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Foreword 
 
The current study is part of a larger Alzheimer’s disease (AD) research project which has 
been ongoing since the year 1998. The main objective is to locate the gene or genes 
responsible for the disease. The project is conducted in collaboration with the geriatric 
division of Landspitali University Hospital and deCODE genetics, which is a population-
based genomic company conducting research into the inherited causes of common 
diseases (http://decode.is). During the first years of the study, neuropsychological 
assessment was performed on mild to moderate AD patients, their siblings and adult 
children between the ages of 40 to 85 years, and a control group or a total of 552 
individuals. In 2002, Smári Pálsson, a member of the original research team, used part of 
the data for his thesis work for the candidate degree in psychology from Copenhagen 
University. The main focus of his thesis was the cognitive performance of siblings of AD 
patients in order to better understand the preclinical stages of the disease. His results 
indicated that undiagnosed AD siblings tend to have impaired verbal and non-verbal 
memory, orientation and attention compared to an age and education matched control 
group without any family history of the disease. Furthermore, 12 percent of the siblings 
had a stronger resemblance to the AD patients than to the rest of the siblings on the 
neuropsychological measures (Pálsson, 2002). In 2005, a reassessment of the siblings and 
the control group was conducted with similar results. As in the previous study, 15 percent 
of the siblings showed impaired performance compared to control group on the same 
neuropsycological measures (Pálsson and Teague, 2007). 
In the beginning of 2006, I was contacted by Smári and offered the opportunity to 
take part in the project by working with the original data assembled on the adult children 
of the AD patients. Furthermore, we decided in collaboration with other members of the 
research team to conduct a reassessment of this group as well as an age and educationally 
matched control group. The purpose was not only to shed further light on the preclinical 
stages of the disease but also to provide much needed information on this at risk group of 
individuals. The reassessment was carried out at the Genetic Research Service Center, at 
deCODE genetics in Iceland in first half of 2007 and constitutes my thesis for the 
candidate degree in psychology from Copenhagen University. 
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ABSTRACT 
 
Previous studies on first-degree relatives of Alzheimer’s disease (AD) patients have 
revealed a higher risk of developing dementia, and that subtle cognitive impairment can 
be detected before overt clinical signs appear using neuropsychological tests. Findings on 
children of AD patients are very scarce within the literature. The main aim of this study 
was to explore the cognitive development of adult children (AC) of AD patients in 
Icelandic pedigrees selected from an ongoing genetic research, over a seven-year period. 
The subjects were 83 AC (age range 46-74) with a family history of AD and a control 
group (NC) constituting 30 individuals (age range 48-73) without any known first-degree 
relative with dementia. Cognitive abilities were assessed using neuropsychological tests 
of orientation, verbal and non-verbal memory, abstract reasoning, language, 
concentration, mental speed, and visuo-spatial and constructional abilities. Participants 
with known central or peripheral nervous disorders were excluded from the study. 
Primary results revealed no statistical difference between the two groups on any of the 
neuropsychological tests from time 1 to time 2, over a seven year period. These findings 
place the onset of subtle cognitive impairments in adult children of AD patients after the 
age of 60 years. When comparing the AC group to 76 AD patients and 92 siblings of AD 
patients, participating in the genetic study, one AC had stronger resemblance to the AD 
group than other AC on the neuropsychological measures. Furthermore, 10% of the AC 
group had stronger resemblance to the siblings of AD patient in the neuropsychological 
measures than the rest of the group, indicating a possible trend within the AC group. 
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PART I: REVIEW OF THE LITERATURE 
 
1. Introduction 
Alzheimer’s disease (AD) is a progressive degenerative disorder affecting the brain and is 
the most common cause of cognitive impairment in older individuals. Prevalence 
numbers increase dramatically with rising age, from around 5% in those aged 65-74 to 
around 20% in people above 85 years of age (Desai and Grossberg, 2005). Given the 
demographic fact that the elderly segment of the population is expanding, AD has 
become one of the greatest health problems, as well as economic burdens, in 
contemporary Western societies. Annual costs in the United States related to AD patients 
are around 100 billion dollars, and over the next 50 years prevalence rates are estimated 
to quadruple in the West. In addition to this, psychological and social burdens on 
caregivers as well as society are enormous. In light of this even a modest delay in the 
progression of the disease due to intervention of any sort could have a major public 
health impact (Standridge, 2004). 
 Since Alois Alzheimer put forward the first description of the disease in 1906, 
great progress has been made within the field of AD. This has been achieved through 
multidisciplinary teams of epidemiologists, clinicians, geneticists, pathologists, 
radiologists, and neuropsychologists (Hardy, 2006). Knowledge regarding risk factors, 
pathogenesis, clinical presentation and therapeutic approaches has increased, although 
many aspects of the disease still remain unclear. 
In recent years the main focus of research has been on the early diagnosis of AD 
rather then the relatively well-established clinical stages of the disease (Lage, 2006). In its 
earliest stages, the disease generally progresses slowly and a number of theories have 
been put forward as to how early the disease can be diagnosed. Most hold that diagnosis 
can be made three to seven years prior to the time when individuals generally seek 
clinical appointments due to symptoms. The question is urgent as early detection would 
serve to maximize the potential therapeutic benefit of available treatments, enhance the 
patients quality of life and, as a result, reduce the burden of residential and nursing care 
services (Blackwell et al., 2004). 
Although no definite preclinical diagnostic markers are available, 
neuropsychological testing has proven to be very effective in the early diagnosis of AD. 
Longitudinal studies of aging and studies on individuals with a strong family history of 
the disease have revealed various cognitive measures sensitive to the earliest stages of the 
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disease. Measures of episodic memory have shown the most sensitivity, followed by 
measures of executive functioning, mental speed and attention, respectively (Bäckman, 
Jones, Berger, Laukka, and Small, 2005). Although neuropsychological testing remains 
the keystone of in vivo early detection, screening and diagnostic tool for AD, other 
approaches such as genetic and neuroimaging are gaining increased leverage. Studies 
already underway combining these approaches are yielding promising primary results 
(Twamley, Ropacki, and Bondi. 2006). 
One group of at risk individuals that has in recent years gained increased attention 
is adult children of AD patients. Despite being a perfectly suited research group, studies 
are scarce and the majority of those that have been published are limited for 
methodological reasons. At the same time reports show that adult children of AD patients 
live their entire lives in fear of developing the disease. Furthermore, they lack information 
regarding prevalence and the likelihood of developing the disease. There is therefore an 
urgent need within the literature for reliable longitudinal researches on this group. Such 
research could conceivably ease the anxiety of these individuals as well as shed further 
light on the preclinical stages of the disease in general (Jarvik and Blazer, 2005; Sager, 
Hermann and La Rue, 2005). 
 
 
2. Memory and aging 
Failures in everyday memory and changes in long-term memory are among the most 
empirically established, socially expected, personally disconcerting, and widely 
misinterpreted features of human aging (Dickerson, Sperling, Hyman, Albert, and 
Blacker, 2007). However, it has proven difficult to estimate at which point these failures 
and changes become abnormal, leading to a research base on memory that has 
accumulated over the last several decades. Generally age-related changes in memory or 
cognition can be divided into three categories: 
 
1. Changes in memory that are age-appropriate and regarded as a common 
consequence of normal aging. 
2. Impairments in memory that are more severe than expected for a given age but not 
severe enough to indicate a disease.  
3. Impairments in cognition that is severe enough to be clinically diagnosed as a 
progressive dementia. 
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Overlaps between these categories and individual differences in cognitive abilities make a 
clear distinction between dementia and memory deficits considered as normal difficult. 
This is reflected in the number of different, inconsistent and poorly defined concepts and 
terminology of mild memory problems within the literature (Twamley et al., 2006). 
 
 
2.1. Normal aging 
Normal aging causes deterioration of various aspects of cognitive functioning while other 
factors seem to remain intact. According to findings the most consistent alterations in the 
aging brain are impairments in episodic memory and executive functioning (Buckner, 
2004). With respect to episodic memory, studies have shown healthy elderly individuals 
to do less well than healthy young controls on measures of delayed recall and recognition 
(Davis et al., 2003; Huh, Kramer, Gazzaley, and Delis, 2006; Lamar, Yousem, and 
Resnick, 2004). The ability to retain information in long-term memory on the other hand 
may not change with age (Fjell et al., 2005). On measures of novel problem solving, 
fluency, and mental flexibility, older subjects tend to perform worse than younger 
controls (Davis and Klebe, 2001; Brickman et al., 2005; Wecker et al., 2005). Taken 
together, to establish a neuropsychological framework, age related changes in memory 
and other cognitive functions are often divided into “fluid” intelligence and “crystallized” 
intelligence. Fluid intelligence involves functions shown to be sensitive to age, such as 
new learning, inductive reasoning or speed of processing. Crystallized intelligence on the 
other hand has to do with previously acquired information, general knowledge and 
comprehension that are affected late in aging (Horn, 1982). Multiple biological factors 
have been suggested as likely contributors to changes in normal aging, such as gene status 
(Wishart et al., 2006), neurotransmitters (Braver and Barch, 2002) and endocrine (Thilers, 
MacDonald, and Herlitz, 2006). However, changes in brain structures are widely 
considered to be a very important factor in age-related cognition (Buckner, 2004). Before 
addressing these changes in more detail, non-invasive methods used to detect and track 
them will be discussed briefly. This will lead to a clearer understanding of changes in 
brain structures as well as other matters that will be dealt with in forthcoming chapters. 
 
 
 9 
2.2. Radiological and physiological brain investigations  
Various imaging techniques are currently available with both structural and functional 
approaches. Structural techniques such as X-ray Computed Tomography Scans (CT scans) 
and the more accurate Magnetic Resonance Imaging (MRI), provide detailed anatomical 
information e.g. measurements of the brain (Mazziotta, 2000). Functional imaging 
techniques on the other hand can be divided into two groups. In the first group are 
techniques that map regional cerebral blood flow (CBF) and metabolic changes related to 
neuronal firing. They include Single Photon Emission Computed Tomography (SPECT), 
Positron Emission Tomography (PET) and functional Magnetic Resonance Imaging 
(fMRI; Rossini and Pauri, 2000). SPECT and PET are related techniques, with the latter 
providing measures on both CBF and glucose metabolism while SPECT only measures 
CBF. Furthermore PET images show more spatial resolution but are at the same time 
more expensive and like the SPECT only detect areas of activation. fMRI, which 
measures the blood oxygen-level dependent signal,1 is on the other hand a combination of 
structural and functional techniques, providing the most precise mapping of the 
techniques mentioned above (Rossini, Calautti, Pauri, and Baron, 2003). 
The second group constitutes techniques that analyze electromagnetic properties 
of the neurons in the brain, by applying extensions versions of ElectroEncephaloGraphy 
(EEG), such as the MagnetoEncephaloGraphy (MEG) and Transcranial Magnetic 
Stimulation (TMS; Rossini and Pauri, 2000). Whereas MEG records the magnetic fields 
induced by neural activity in the brain, TMS works in the opposite manner. TMS 
stimulates the brain in a non-invasive way, using rapidly alternating magnetic fields, 
expanding ways to study the functionality of the circuitry and connectivity og the brain, 
and may even have therapeutic potential (Rossini and Rossi, 2007). 
 
 
2.3 Memory in the normal aging brain 
Neuropsychological, physiological, and brain imaging studies indicate that the prefrontal 
cortex and the medial temporal lobes (MTL) are most sensitive to age-related changes 
(Small, 2001). In accordance with these findings, decreased brain volume in areas critical 
for cognition such as the hippocampus and cerebral cortex have been well established, 
                                                
1 When neurons become active they require more oxygen and glucose, this causes alteration in proportions 
of oxygenated to deoxygenated blood in that area. The brain tissue in that area fails to extract all the 
additional oxygenated blood, which the magnetic-resonance scanner detects (Rossini and Rossi, 2007). 
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with the frontal cortex showing the greatest change (Albert, 1997; DeCarli et al., 2005). 
Structural analyses have revealed preferential gray matter volume loss and reduced white 
matter integrity in frontal brain regions (Charlton, McIntyre, Howe, Morris, and Markus, 
2007; Duarte, Ranganath, Truillo, and Knight, 2006; Salat et al., 2004; Shenkon et al., 
2005; Sullivan and Pfefferbaum, 2006). These frontal changes affecting the frontal striatal 
system are the most likely causes of reduced executive function and may also be central 
to memory difficulties experienced by healthy elderly individuals. Reduced executive 
functioning is known to affect memory by impairing strategic, controlled processing at 
encoding and retrieval (Buckner, 2004). 
 The MTL structures including the hippocampal formation, perirhinal cortex and 
the entorhinal cortex play a vital role in long-term declarative memory. Although not 
being the eventual site of memory storage, the MTL operates for a limited time period in 
the consolidation of memory traces, binding together different neocortical structures 
involved in memory representations (Alvarez and Squire, 1994). Several studies on non-
demented aging have found a correlation between memory performance and atrophy in 
the MTL or substructures of the MTL (Golomb et al., 1996; Launer et al., 1995; 
Rodrigues and Raz, 2003). Furthermore, studies on AD patients have shown atrophy, 
cellular pathology and cell loss in MTL structures that lead to severe memory 
impairments (Ridha et al., 2006; Scahill, Schott, Stevens, Rossor, and Fox, 2002). The 
involvement of the MTL in AD and the high prevalence of AD in older adults have raised 
the question whether AD represents accelerated normal aging or a distinct disease entity 
(Buckner, 2004). Accumulating evidence has refuted the suggestion of a unitary factor 
framework of aging with cognitive declining falling along a single continuum ending in 
AD. Firstly, evidence of a positive association between hippocampal volume and memory 
performance seems to be weaker than previously thought (Van Petten, 2004). Secondly, 
diagnostic and screening difficulties of earliest stages of AD make it hard to obtain 
samples free of the disease. This reduces the reliability of studies revealing association 
between volume reduction in MTL and memory performance in healthy older adults 
(Buckner, 2004). Lastly, many older adults experiencing healthy aging are free of 
pathology or memory impairments associated with AD (Gómez-Isla et al., 1996). Similar 
findings have been reported from postmortem studies on non-demented individuals up to 
the age of 89. These studies show little, if any neocortical pathology (Morris et al., 1991). 
For these reasons a multi factor framework of aging has been suggested with separation 
of memory impairments linked to AD and executive dysfunction associated with a 
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disrupted frontal-striatal system (Andrews-Hanna et al., 2007). In line with this opinion, 
recent findings of structural changes in white matter integrity suggest an even larger-
scaled brain system to be involved in aging with widespread disruptions in higher-order 
brain systems reaching from anterior to posterior areas of the brain (see in Andrews-
Hanna et al., 2007). 
 
 
2.4 Terminology of mild memory problems 
Over the past several decades a variety of terms have been used within the literature to 
discuss the transitional stages between normal ageing and early dementia (Petersen, 
2004).  In 1962 Kral proposed the term benign senescent forgetfulness referring to non-
disabling memory deficits, such as inability in recalling data and experiences (see in 
Panza et al., 2005). In 1986 the National Institute of Mental Health (NIHM) proposed the 
term age-associated memory impairment (AAMI) as a diagnostic entity for age related 
changes in memory. The NIHM criteria include the following: 1) presence of gradual 
memory decline in persons over the age of 50; 2) score of at least 1 standard deviation 
below the mean for younger adults on a well standardized memory tests; 3) adequate 
intellectual function; 4) absence of dementia or other diseases that affect memory (Crook, 
et al., 1986). The criteria of AAMI has been criticized for lack of practical utility by not 
addressing progression, and therefore discriminating poorly between those who will 
develop dementia and those that remain cognitively stable (Panza et al., 2005). 
Furthermore others have pointed out the pronounced heterogeneity within the AAMI 
population suggesting that almost all older adults could be diagnosed with AAMI (Shah 
et al., 2000). 
Age-associated cognitive decline (AACD) was proposed by a taskforce of the 
International Psychogeriatric Association, referring to multiple cognitive domains 
assumed to decline in normal aging. According to AACD criteria a score 1 standard 
deviation below age- and educationally based norms is necessary on neuropsychological 
tests measuring multiple cognitive domains (Levy, 1994). Other proposals have been put 
forward, such as cognitive impairment no dementia (CIND) and age related cognitive 
decline (ARCD) as described in the DMS-IV (Panza et al., 2005; for review see Mariani, 
Monastero, and Mecocci, 2007). 
 Mild cognitive impairment (MCI) has in recent years received considerable 
research attention for being recognized as a pathological condition as opposed to 
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manifestation of aging, and a promising clinical utility (Petersen, 2004). In the original 
criteria proposed by Petersen and co-workers in 1999, MCI was characterized by the 
following: 
 
1. A self-reported memory complaint, preferably corroborated by a family member. 
2. A detectable memory deficit, abnormal for age (about 1.5 standard deviation 
below the norm). 
3. Normal general cognitive functioning aside from memory. 
4. Relatively intact activities of daily living such as driving a car and balancing a 
checkbook. 
5. Absence of dementia. 
        (Petersen et al., 1999; 2001) 
 
When this definition was used in population-based studies, it became clear that it only 
constituted a relatively small group, it didn’t represent other individuals with a much 
broader form of mild cognitive deficits in other cognitive functions, such as attention and 
language (Mariani et al., 2007). For this reason Peterson (2004) revised the original 
criteria by adding four different MCI subtypes: 1) aMCI, constituting the original MCI 
criteria; 2) single non memory MCI (snmMCI), with isolated impairment of other 
cognitive domains than memory; 3) multiple domain amnestic MCI (mdMCI+), with 
multiple cognitive domains slightly impaired, including memory; 4) multiple domains 
non amnestic MCI (mdMCI-), characterized by slight impairment of multiple cognitive 
domains but without memory deficits (Petersen, 2004). 
In general, longitudinal studies have shown MCI patients at increased risk of 
developing dementia, with estimates varying somewhat depending on study designs. 
Clinical studies indicate yearly incidences of about 10-15%, while population-based 
studies report lower rates, ranging from 5-10% per year (Petersen, 2001; DeCarli, 2003; 
Panza et al, 2005). Results from population-based studies have also shown a significant 
level of reversion (20-25%) from MCI to normal cognition and functioning (Larrieu et al., 
2002; Palmer, Wang, Backman, Winblad, and Fratiglioni, 2002; Petersen et al., 1999; 
Ritchie, Artero, and Touchon, 2001). In relation to risk factors of AD, most attention in 
MCI has focused on the aMCI variant and in recent years mdMCI+ (Small, Gagnon, and 
Robinson, 2007; Tabert et al., 2006). Similar neuropathology to AD, mainly involving the 
MTL structures, has been established with an intermediate degree between that found in 
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normal aging and AD (Rusinek et al., 2003; Schott, Kennedy, and Fox, 2006). In line 
with this aMCI and mdMCI+ are considered to have a higher likelihood of converting to 
AD, while snmMCI and mdMCI- are more likely to convert to non-AD dementia 
(Petersen, 2004). Studies have revealed mixed results regarding this issue with some 
confirming it (Busse, Hensel, Guhne, Angermeyer, and Riedel-Heller, 2006), while other 
refute it showing aMCI patients evolving to both AD and non-AD dementia and 
nondemented MCI subtypes progressing to AD (Fischer et al., 2007). According to these 
findings MCI appears to be an extremely heterogeneous clinical entity with respect to 
etiology, clinical presentation and outcome. Much work is still required in order to 
establish a uniform diagnostic classification and more thoroughly defined operations 
criteria before MCI becomes universally accepted (Mariani et al., 2007; Small, 2007). 
Some have pointed out that the term MCI it not as useful as prodromal or 
preclinical AD (Dubois, 2000). Preclinical AD is a more general term referring to early 
pathological and cognitive deficits that may allow the identification of those that are at 
increased risk of being diagnosed with the AD in the nearest future, e.g. those with aMCI. 
Even though diagnosis is difficult at this stage it would provide an entity signifying 
patients with AD neuropathology and early cognitive markers (Small, 2007). 
 
 
3. Dementia 
Dementia refers to a disease of the brain, usually chronic and progressive, resulting in 
impairment of memory and other cognitive functions severe enough to cause impairment 
in social and occupational functioning in persons with unclouded consciousness 
(American Psychiatric Association [APA], 1994; World Health Organization [WHO], 
1994). The prevalence of dementia is age-dependent, approximately doubling every five 
years, being 2% for age 65 but around 23% for those 85 years of age (Rocca, 1994; 
Rithchi and Lovestone, 2002). In dementia there are disturbances of 
 
multiple higher cortical functions, including memory, thinking, orientation, 
comprehension, calculation, learning capacity, language and judgment. 
Consciousness is not clouded. The impairments of cognitive function are 
commonly accompanied, and occasionally preceded, by deterioration in emotional 
control, social behaviour, or motivation 
(WHO, 1994, F00-F03). 
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The identification of dementia is necessary for specific diagnosis of any of the dementia 
syndromes, such as vascular dementia, because the presence of deficits in memory or 
cognition are not equivalent to early dementia. Delirium and depression can often be 
difficult to distinguish from dementia, especially because they often coexist (APA, 1994; 
WHO, 1994). 
The American Psychiatric Association Diagnostic and Statistical Manual of 
Mental Disorders version 4 (DSM-IV; APA, 1994) and The World Health Organization 
10th International Classification of Diseases (ICD-10; WHO, 1994) are the most 
commonly used systems for the diagnosis of dementia (Naik and Nygaard, 2007). The 
most common dementia syndromes are the following: 
 
1. Alzheimer’s disease  
Alzheimer’s disease is the leading cause of dementia accounting for 65-70% of all 
cases as well as being the best known of the dementia  (Rathmann and Conner, 
1984). AD will be discussed in greater detail in the following chapters. 
 
2. Vascular Dementia (VAD) 
A permanent cognitive impairment resulting from cerebrovascular disease most 
frequently associated with hypertension. It is the second largest cause of 
dementia, constituting 15-20% of all cases in the elderly population worldwide 
(Román, et al., 2004). The onset can vary from abrupt (stroke) to being more 
insidious with stepwise deterioration (Geldmacher and Whitehouse, 1996). One 
form of VAD that is most often encountered by neuropsychologists is the Multi-
infarct dementia (MID) (Lezak, 2004). MID represents a term for a condition 
caused by repeating infarctions, usually at several different sites, leading to 
widespread cognitive impairment (Chui et al., 1992). Two types have been 
recognized: 1) cortical atherosclerotic dementia (CAD), repeated infarctions 
affecting areas in the cerebral cortex supplied by the larger blood vessels, and 2) 
subcortical arteriosclerotic dementia (SAD) produced by infarctions and/or 
ischemia affecting the arterioles feeding the subcortical structures (Chui, Mack 
and Jackson, 2000). Two types of SAD are generally recognized, lacunar stroke 
and Binswanger’s disease, and these often occur together (Geldmacher and 
Whitehouse, 1997). Differentiating cognitive effects of MID from those of AD 
has proven to be difficult. Several important differences help in that respect. 
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Firstly, the onset symptoms of MID are generally more acute and fluctuating in 
severity. History of risk factors related to stroke, especially hypertension, are 
nearly universal in MID patients and a previous history of stroke is common. MID 
patients show better performance on memory tests than AD patients, but they 
show reduced output on unstructured construction tasks and verbal description. 
Lastly, focal neurological signs are clearly identifiable (Reed et al., 2004; 2007; 
Reichman, Coyne, and Shah, 1993). 
 
3. Frontotemporal dementia (FTD) 
FTD, formerly called Pick’s disease, is a progressive dementia associated with 
focal atrophy of the frontal and anterior temporal regions of the brain (Snowden, 
Neary, Mann, and Benson, 1996). Overall it is estimated that FTD accounts for 
around 20% of degenerative dementia with a presenile onset (Ikeda, Ishikawa, 
and Tanabe, 2004; Snowden, et al., 2002). It usually affects people between the 
age of 35-75, with a median onset of around 58 and is more common in people 
with a positive family history of dementia. (Weder, Aziz, Wilkins, and Tampi, 
2007). Clinically, FTD is characterized by behavioral problems, changes in 
personality and/or executive impairment, or as a primary progressive aphasia 
syndrome. Three subtypes of FTD have been recognized; the first being a frontal 
variant of FTD (FvFTD), characterized by personality changes, behavioral 
abnormalities and poor insight with an insidious onset. Second is semantic 
dementia (SD), linked with bilateral atrophy of the middle and inferior temporal 
neocortex. These patients show deficits in language, such as loss of memory for 
words or a loss of the meaning of words. Finally there is progressive non-fluent 
aphasia (PNFA), which is mainly a disorder of expressive language, characterized 
by changes in fluency, pronunciation or word finding difficulties (Boxer and 
Miller, 2005; Weder et al., 2007). FTD is frequently mistaken for AD and there 
seems to be a lack of consistency in findings trying to differentiate the cognitive 
profiles of FTD and AD (Hutchinson and Mathias, 2007). Despite this the 
following criteria have proven useful in differentiating FTD from AD: early loss 
of social and personal awareness, hyperorality, progressive loss of speech, and 
stereotyped and perseverative behaviors (Rosen et al., 2002).  
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4. Dementia with Lewy bodies (DLB) 
DLB is a progressive dementia, most often accompanied with parkinsonism, 
dopamine antagonist sensitivity, and psychiatric symptoms such as recurrent 
visual hallucinations and fluctuating mental status (McKeith et al., 1996). It is 
estimated that DLB accounts for around 10-15% of dementia in older people 
(Saldana, Mullolt, Auilar, Bonastre, and Marin, 2007). The defining 
neuropathological features are Lewy bodies, protein deposits found in the cortex, 
the paralimbic area and the substantia nigra. Patients with LBD are 
distinguishable from AD patients by prominent visuospatial deficits but show 
better performance on memory test and often show deficits related to 
frontosubcortical dysfunction (McKeith et al., 2005). 
 
5. Other Dementias 
Many other diseases can cause dementia such as: Parkinson’s disease, Huntington 
disease, progressive supranuclear palsys disease, Creutzfeldt-Jakob disease, 
Multiple Sclerosis (MS) and AIDS (Lezak, 2004). Other dementias are potentially 
reversible, including drug or alcohol related dementias, dementias caused by 
metabolic inregularities e.g. Thyroid and Vitamin B12 deficiency, and dementia 
due to depression (Lezak, 2004). 
 
 
4. Alzheimer’s disease (AD) 
 
4.1. History of AD 
Alois Alzheimer reported the first case of AD in 1906 at a meeting of the South Western 
German Psychiatrists in Tübingen, Germany (Ballenger, 2006). In his lecture and later in 
a report published in 1907, Alzheimer described the symptoms of Augustine D., a 51-
year-old patient. Augustine D. suffered from progressive cognitive decline and behavioral 
changes over a 5-year period, ending in her death (Alzheimer, 1907). Ten years later this 
disease was given his name, “Alzheimer’s disease”, by his mentor Emil Kraepilin (Lage, 
2006). Of course, AD existed before 1906, but the symptomatology of the disease had not 
previously been described in such detail. Furthermore, Alzheimer was the first to describe 
microscopic lesions in the brain, later known as neurofibrillary tangles, in full detail and 
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associate them with the clinical characteristics of AD (Ballenger, 2006; Goedert and 
Bernadino, 2007; Lage, 2006). 
 Over the next decades, or up until the 1960s, AD and dementia in general did not 
receive much research attention. This was reflected in many of the contemporaneous 
neurology textbooks where AD and dementia were regarded as very “rare”, and little 
space was devoted to a discussion of the disease (Libon, Price, Heilman, and Grossman, 
2006). This was mostly due to Kraepelins decision in 1910 to distinguish between 
presenile and senile dementia in his eighth edition of his Treatise on Psychiatry. In this 
work, AD was regarded as a presenile dementia and it was furthermore contended that 
senile dementia was another type of disorder (Hardy, 2006; Lage, 2006). 
 Between 1960 and 1970, AD became recognized as the major cause of late life 
dementia, with the shift being due to both demographic and scientific events. During this 
time, life expectancy was increasing which called for a higher quality of life for the 
elderly. Gerontology and geriatric medicine became an important field within the 
scientific community and in the USA for instance the federal government started 
investing in aging. One important scientific development was the findings from the 
Newcastle-Upon-Tyne studies of Martin Roth and associates. In their studies they found 
association between the number of senile plaques in the brains of 60 individuals and 
neuropsychological and functional tests. Using a systematic analysis of behavior, they 
provided for the first time a direct association to pathology. This made way for 
systematic clinical pathological studies of the disease (see in Libon et al., 2006). 
Furthermore, they established that the majority of patients with senile dementia had AD, 
contradicting the older view of the two being separate disorders. AD had become the 
center focus of attention and has remained so ever since (Lage, 2006). 
 Since the “rediscovery” of AD in the 1970s, much has been accomplished in 
terms of gaining understanding of the disease. However, as the 100th anniversary of 
Alzheimer’s initial description of the disease was celebrated in 2006, it is also evident 
that many gaps remain to be filled (Hardy, 2006). 
 
 
4.2. Diagnosis of AD 
AD is a chronic neurodegenerative disorder that is characterized by progressive cognitive 
decline, most often starting with impairments in memory and ending in global cognitive 
deterioration (Howieson, et al., 1997). Given the insidious nature of the disease and the 
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severe effects it has on patients, as well as their caregivers, an early diagnosis is of the 
utmost importance (DeKosky and Marek, 2003; Desai and Grossberg, 2005; Mittelman, 
Roth, Clay, and Haley, 2007; Richards and Hendrie, 1999). In recent years, considerable 
progress has been made in terms of better understanding the cognitive profile of very 
early AD and its neural basis. However, due to the overlapping of symptoms of healthy 
aging and the first manifestations of AD, the transitional zone is still unclear (Clark and 
Karlawish, 2003; Nestor, Scheltens, and Hodges, 2004). This results in patients not being 
diagnosed until they become symptomatic, most likely reducing the prevention effect of 
any available medical treatment (Desai and Grossberg, 2005; Gauthier, 2005). 
 The lack of markers to identify positive AD in vivo makes the diagnosis, without 
a autopsy report, one of exclusion where all other possible causes for dementia or 
memory disorder have to be ruled out (Lezak, 2004). A clinical diagnosis of AD relies on 
a variety of information from different sources following specific diagnostic guidelines 
(Geldmacher and, Whitehouse, 1996, 1997; McKhann, et al., 1984; Tierney et al., 1988). 
This information includes family and medical history; neurological, psychiatric and 
clinical examination; neuropsychological testing and laboratory testing (McKhann, et al., 
1984). Three main sets of diagnostic criteria have become widely accepted over the 
years, greatly improving the reliability of clinical diagnosis. They are the following: 
 
1. The Diagnostic and Statistical Manual of Mental Disorders 4th edition (DSM-IV, 
APA, 1994). 
2. International Classification of Mental and Behavioral Disorders, 10th edition 
(ICD-10; WHO, 1994). 
3. The National Institute of Neurological, Communication disorders and 
Stroke/Alzheimer’s disease and Associated Disorders Association (NINCDS-
ADRDA) research criteria for AD (McKhann et al., 1984). 
 
The NINCDS-ADRDA criteria, unlike the other two, provides three levels of diagnostic 
confidence. First is probable AD, which presents the highest confidence level of 
diagnosis, ante mortem, reflecting the typical course with gradual onset and continuing 
cognitive decline. Second is possible AD that is diagnosed when patients demonstrate an 
atypical course of dementia or coexisting potential dementia illnesses with AD being the 
primary. Finally is the definite AD, diagnosis given when there is confirmation either by 
biopsy or autopsy (Villareal and Morris, 1998). Probable and possible diagnoses both 
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require dementia to be established using a clinical instrument such as the Mini Mental 
State Examination (MMSE) or the Dementia Rating Scale (DRS-2), and later confirmed 
using formal neuropsychological testing (Bianchetti and Trabucci, 2001). In addition to 
confirmatory evidence, the neuropsychological test provides valuable information in 
determining the pattern of impairment and assessing changes over time with or without 
interventions (McKhann et al., 1984; see table 1). 
 The NINCDS-ADRDA and the DMS-IV criteria have been validated against 
neuropathological gold standards showing sensitivity from 65-98% (Kazee et al., 1993; 
Klatka, Schiffer, Powers, and Kazee, 1996; Lopez et al., 2000; Nagy, et al., 1998; 
Petrovitch, et al., 2001; Varma, et al., 1999;) and specificity against other dementias from 
23-88% (Dewan and Gupta, 1992; Kazee et al., 1993; Varma, et al., 1999). Even though 
it is difficult to assess accurately the estimates above, due to the different pathological 
standards used in some studies, it has been pointed out that the diagnostic specificity is 
insufficient (Foster, 2007; Nagy, et al., 1998; Varma, et al. 1999). In their study from 
1999, Varma and associates demonstrated that the NINCDS-ADRDA criteria failed to 
accurately differentiate AD from frontotemporal dementia (FTD). They likewise reported 
that many of the other non-AD dementias can fulfill the NINCDS-ADRDA criteria, thus 
raising the possibility of them being caterorized as AD in previous AD studies. Others 
have shown that the specificity estimates have risen from 52% to 88% over a 20-year 
period, indicating improvement in the diagnosis of other Dementia disorders (Lopez, et 
al., 2000). 
 This discussion has lead to the consensus that revision is needed on the diagnostic 
criteria for AD due to its age, and the risk of the criteria losing their relevance. Apart 
from strengthening its sensitivity and specificity, more emphasis needs to be placed on 
early diagnosis and the new knowledge that has been gathered over the last two decades. 
One such proposal has been put forward by an international workgroup convened in 
2005, where a revised set of diagnostic criteria for AD was introduced (Foster, 2007). 
Dubois and colleagues (2007) in their revised version focus the attention on the 
distinctive biology of AD rather than recognition of a clinical syndrome. They suggest 
the use of molecular imaging, body-fluid biomarkers and genetic testing to maximize the 
specificity of diagnosis. In their view, these biomarkers allow for the abandonment of 
traditional diagnostic techniques, while also opening up the possibility of an earlier and 
more specific diagnosis.. According to the criteria, in order to be diagnosed with probable 
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AD, the affected individual has to fulfill the core diagnostic criteria (criterion A) and at 
least one of the supportive biomarkers criteria (B, C, D, or E, see table 2). 
Although the ideas of Dubois and colleagues have a lot to recommend them, it has been 
pointed out that they should rather be regarded as a crucial framework for future 
discussion than fully constructed diagnostic criteria. In its current state, the criteria would 
be impossible to implement, given that the operational definitions of methods and 
abnormal results are still lacking (Foster, 2007). 
As is evident from these criteria, the most reliable way to diagnose AD is by 
neuropathology and this is according to most criteria necessary for the diagnosis of 
definite AD. Three types of post mortem criteria have become the most widely used. The 
first is the Khachaturian criteria published in 1985, which provided absolute cutoff scores 
for the diagnosis of AD with the numbers of plaques in various brain areas. The absolute 
number of plaques needed is dependent on age and the presence or absence of clinical 
history of dementia. The second is a standardized neuropathological criterion, stemming 
from the initial Khachaturian criteria put forward by the Consortium to Establish a 
Registry for Alzheimer’s Disease (CERAD) in 1991. They introduced a semi-quantitative 
score in 3 neocortical brain areas rather than a cut off score, relying on primary neuritic 
plaques of the diffuse type rather than all senile plaques (Mirra, et al., 1991). Lastly, the: 
Diagnostic criteria for the neuropathological assessment of Alzheimer’s disease, 
proposed by The National Institute on Aging-Reagan Institute. This latest criteria has the 
most restrictive guidelines and unlike the other two, relies heavily on neurofibrillary 
tangles given that they seem to obey a relatively reliable progression across different 
brain areas with increasing severity of the disease. Furthermore, these new guiding 
principles put less emphasis on quantitation and cut off score and separate the 
neuropathological diagnosis from the availability of a history of dementia (Hyman, 
1998).  
 
 
4.3. Disease process and clinical subtypes 
Initial symptoms in prototypical AD begin insidiously which makes marking a precise 
starting point very difficult. However, diagnosis is normally made 2-4 years from the 
onset of the disease (Bianchetti and Trabucchi, 2001; Bond, Stave, Sganga, O’Connell, 
and Stanley, 2005). In the early stages of the disease, symptoms are subtle with the 
person being less spontaneous or productive in usual daily activities. The first cognitive  
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Table 1. 
The NINCDS/ADRDA clinical criteria for Alzheimer’s disease (Adapted from McKhann 
et al., 1984). 
Criteria for the clinical diagnosis of probable Alzheimer’s disease: 
• Presence of dementia established by clinical examination and confirmed by neuropsychological tests. 
• Deficits in at least two areas of cognition. 
• Progressive worsening of memory and other cognitive functions. 
• No disturbance of consciousness. 
• Onset between ages 40 and 90 years, most often after 65. 
• Absence of systemic disorders or other brain diseases that could account for the dementia. 
 
The diagnosis is supported by: 
• Progressive deterioration of specific cognitive functions such as language (aphasia), motor skills 
(apraxia) and perception (agnosia). 
• Impaired activities of daily living and altered patterns of behavior. 
• Family history of dementia. 
• Evidence of cerebral atrophy on CT with progression documented by several observation. 
 
Features consistent with the diagnosis: 
• Plateaus in the course of the disease. 
• Associated psychiatric symptoms. 
• Neurological signs, especially in advanced disease, including motor signs, such as increased muscle 
tone, myoclonus, or gait disorders. 
• Seizures in advanced disease. 
• Normal CT for age. 
 
Diagnosis of AD is unlikely if:  
• Sudden, apoleptic onset. 
• Focal neurological findings such as hemi paresis, sensory loss, visual fields deficits, and in 
coordination early in the course of the illness. 
• Seizures or gait disturbances at the onset or very early in the course of the illness. 
 
Criteria for the diagnosis of possible Alzheimer’s disease: 
• May be made on the basis of the dementia syndrome, in the absence of other neurological, psychiatric, 
or system disorders sufficient to cause dementia, and in the presence of variations in the onset, in the 
presentation, or in the clinical course. 
• May be made in the presence of a second systemic or brain disorder sufficient to produce dementia, 
which is not considered to be the cause of dementia. 
• Should be used in research studies when a single, progressive severe cognitive deficit is identified in 
the absence of other identifiable causes. 
 
Criteria for definite Alzheimer’s disease: 
• Clinical criteria for probable AD. 
• Histopathologic evidence obtained by biopsy or autopsy. 
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Table 2.  
Revised diagnostic criteria for AD proposed by international workgroup convened in 
2005 (Adapted from Dubois, et al., 2007). 
Probable Alzheimer’s disease: A plus one or more supportive features B, C, D or E 
Core diagnostic criteria 
A. Presence of an early and significant episodic memory impairment that includes the following 
features: 
1. Gradual and progressive change in memory function reported by patients or informants over more 
than 6 months. 
2. Objective evidence of significantly impaired episodic memory on testing: this generally consists of 
recall deficits that does not improve significantly or does not normalize with cueing or recognition 
testing and after effective encoding of information has been previously controlled. 
3. The episodic memory impairment can be isolated or associated with other cognitive changes at the 
onset of AD or as AD advances. 
 
Supportive features 
B. Presence of medial temporal lobe (MTL) atrophy 
• Volume loss of hippocampi, entorhinal cortex, amygdala evidence on MRI with qualitative rating using 
visual scoring (referenced to well characterized population with age norms) or quantitative volumetry of 
regions of interest (referenced to well characterized population with age norms). 
 
C. Abnormal cerebrospinal fluid biomarker 
• Low amyloid #1-42 concentrations, increased total tau concentrations, or increades phospho-tau 
concentrations, or combinations of the three. 
• Other well validated markers to be discovered in the future. 
 
D. Specific pattern of functional neuroimaging with PET 
• Reduced glucase metabolishm in bilateral temporal parietal regions. 
• Other well validated ligands, including those that forseeably will emerge such as Pittsburg compound B or 
FDDNP. 
 
E. Proven AD autosomal dominant mutation within the immediate family 
 
Exclusion criteria 
History 
• Sudden onset. 
• Early occurrence of the following symptoms: gait disturbances, seizures, behavioural changes. 
 
Clinical features 
• Focal neurological features including hemiparesis, sensory loss, visual field deficits. 
• Early extrapyramidal signs. 
 
Other medical disorders sever enough to account for memory and related symptoms 
• Non-AD dementia, major depression, cerebrovascular disease, toxic and metabolic abnormalities, MRI 
FLAIR or T2 signal abnormalities in the MTL that are consistent with infection or vascular insults. 
 
Criteria for definite AD 
AD is considered definite if the following are present: 
• Both clinical and histopathological (brain biopsy or autopsy) evidence of the disease, as required by the 
NIA-Regan criteria for the post-mortem diagnosis of AD; criteria must both be present. 
• Both clinical and genetic evidence (mutation on chromosome 1, 14, or 21) of AD; criteria most both be 
present. 
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symptoms are most often deficits in memory, especially episodic memory, manifested in 
early loss of memory for everyday events. Examples could be forgetting where things are 
placed, important appointments or names. There are also signs of deficits in executive 
function characterized by difficulties in problem solving and judgment. Language 
difficulties such as finding appropriate words and hesitation in speech are common, as is 
temporal and geographical disorientation. Although these problems don’t necessarily 
disturb day-to-day function, they can result in feelings of anxiety and depression 
(Rathmann and Conner, 1984). 
Conducting day-to-day tasks becomes increasingly difficult as the disease 
progresses and memory deficits become more frequent and severe, which in turn 
increases the individual’s dependence on others (in most cases relatives). Memory is 
mostly limited to long established memories and the patients may become confused at 
this stage, failing to recognize relations and faces. At this stage language-use is often 
limited to a number of phrases, with little comprehension of written and spoken language. 
Disorientation becomes more acute, resulting for example in patients getting lost in 
familiar settings. Behavioral problems start to become apparent at this stage, which 
complicates the clinical picture. They include aggression, delusions, suspiciousness, 
restlessness, wandering, and visual or auditory hallucinations (Villareal and Morris, 
1998). 
 In the advanced stage of AD the patient is totally dependent on others regarding 
day-to-day activities. Little remains of memory and speech is close to mutism. As the 
deterioration continues towards the final stages (usually after five to ten years), the 
patients lose the ability to communicate, think and move. They essentially revert to a state 
of infantile behavior. Death ensues from infection or other chronic diseases (Rathmann 
and Conner, 1984; Villareal and Morris, 1998). 
 Due to the different age of onset of AD and the apparent clinical difference, 
scientist have suggested the distinction of AD into early-onset, staring before the age of 
65, and late-onset, which is a more common type and starts after the age of 65. Early 
onset AD seems to have a more progressive rate of decline resulting in shorter survival, 
rapid deterioration of cognitive and language abilities, more widespread neurochemical 
abnormalities, and a larger density of neurohistologic lesions (Villareal and Morris, 
1998). Early onset AD is rare, giving support to another common distinction of AD into 
familial and sporadic AD (Swartz, Black, and George-Hyslop, 1999). Familial AD seems 
to often have an inheritance pattern whereas no other cases of AD are evident in the 
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sporadic form. Another clinical subtype recognized is the posterior variant. This form 
differs from the prototypical form by prominent visual disturbances occurring in the 
earliest stages such as visual agnosia, prosopagnosia, alexia and Balint’s syndrome. 
Memory is often preserved relatively intact in the earlier stages even though full dementia 
eventually develops (Lezak, 2004). 
 
 
4.4. Epidemiology and the impact of AD  
AD is the leading cause of dementia, accounting for 65-70% of all cases as well as being 
the fourth leading cause of death due to diseases in people aged 65 and older (Skoog, 
Nilsson and Palmez, 1993; Morris, 1994; Launer et al., 1999). The onset of AD can vary 
dramatically between individuals but relatively few seem to be diagnosed before the age 
of 50, although data on the matter are scarce (Ernst and Hay, 1994). People diagnosed 
before the age of 65 are often referred to as having an early-onset of the disease, as 
opposed to having a late-onset referring to those diagnosed after the age of 65 (APA, 
1994). The early onset form of AD is rare, constituting only around 10% of all AD cases, 
with around 1-2% running in families (Munoz and Feldman, 2000; Swartz et al., 1999). 
Worldwide research has shown an estimated prevalence of AD for those aged 65 and 
older from 1-15% (APA, 2004; Alloul et al., 1998; Canadian Study of Health and Aging 
Working Group (CSHA), 1994; Evans et al, 1989; Letenneur et al., 1993; Jorm and 
Jolley, 1998;). Prevalence number seem to rise dramatically with age from being around 
5% in people aged 65-74 to around 20% in people over 85 years of age (Desai and 
Grossberg, 2005; Herbert, Scherr, Bienias, Bennet, and Evans, 2003). Slightly higher 
proportions have been found among African-American and Hispanic populations (Tang, 
et al., 2001). Prevalence numbers vary between studies making them difficult for 
comparison, most likely due to different methodologies used on each occasion. For 
instance, studies which include mild cases of AD or are based on convenience samples 
report higher level of prevalence than those that are not (Ankri and Poupard, 2003; 
Kukull, et al., 2002). The same problem applies to incidence rates of AD but in a recent 
carefully designed cohort study, Kukull and associates (2002) attempted to solve this 
methodology related difficulty. According to their report, AD rates rise from 2,8 new 
incidences per 1000 persons per year for individuals aged 65-69, to 27,5 for those aged 
80-85 and finally 56,1 for people above the age of 90. Incidence rates seem to triple for 
every five years from the age of 65 onward, but after the age of 85 the increase is less, or 
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around a 1,3 fold increase (Kukull et al., 2002). Translated into population statistics 4,5 
million people were diagnosed with AD in the United States in 2000 and this number will 
rise to 13,2 million individuals in the year 2050 if no cure becomes evident (Herbert et 
al., 2003). It has been estimated that if the onset of AD could be delayed by five years on 
the average, incidences of new cases could be reduced by half (Brookmeyer, Gray and 
Kawas, 1998). Such a reduction would not only benefit the patients and their caregivers 
but also the economy of societies worldwide. AD has already become an economic 
burden with annual cost in the USA ranging from approximately 18.000 dollars for 
patients with mild AD to 36.000 dollars for severe AD patients, combining for a total cost 
of 100 billion per year (Ernst and Hay, 1994; Leung, Yeung, Chi, and Chu, 2003). 
 
 
4.5. Risk factors of AD 
AD has a complex etiology where both environmental and genetic factors seem to 
influence the disease pathogenesis (Rogaeva, Kawarai, and George-Hyslop, 2006). 
Studies on monozygotic twins have shown a concordance rate from 50-80%, which 
indicates a strong genetic influence, but are at the same time not high enough to exclude 
other non-genetic factors (Bergem, Engdal, and Kringlen, 1997; Gatz et al., 2006). The 
main risk factors for AD are discussed in the following sections. 
 
 
4.5.1. Genetic predisposition 
AD is often divided into familial AD, referring to the presence of at least on first-degree 
relative with the diseas, and sporadic AD, when no previous cases within the family are 
known (WHO, 1994). Sporadic AD is a much more common type and constitutes around 
95% of all cases (Rogaeva et al., 2006). Having one relative diagnosed with AD triples 
the risk for other members of the family and increases to seven fold if there is more than 
one relative affected (van Duijn et al, 1991). So far, four AD genes have been recognized: 
A!PP (Goate, 2006; Goate et al., 1991), presenilin 1 (PS1; Sherrington et al., 1995), 
presenilin 2 (PS2; Rogaev et al., 1995) and Apolipoprotein E (APOE; Saunders et al., 
1993; see table 3).The common pathology effects of these genes, mostly due to mutation  
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Table 3.  
Currently identified AD genes (derived from Mayeux, 2006 and Rogaeva et al., 2006). 
Chromosome Gene Age-at-onset Pattern Variants 
Ch21q21 A#PP 30-65 AD* 25 
14q24.3 PS1 16-65 AD* 155 
1q31-q42 PS2 40-85 AD* 12 
19q13.2 APOE 50-85 Familial 3 isoforms 
*AD indicates autosomal dominant 
 
except in the APOE, are to alter A#PP processing and promote A#2 deposition (St 
George-Hyslop and Petit, 2004). The A#PP, PS1 and PS2 are inherited autosomally and 
mutations have been found in large multigenerational families and they are believed to 
cause at most half of all early-onset AD cases. The most frequently involved of the three 
genes, with around 155 mutations or variants found, is the PS1. making it the most 
common cause of familial early-onset disease (Mayeux, 2006; Schellenberg, 2006). 
The APOE gene, contrary to the other genes, operates as an AD risk factor and 
modifies the age of onset for the late- and the early-onset types of AD (Serretti, Artioli, 
Quartesan, and Ronchi, 2005). APOE is a polymorphic plasma protein that binds to a 
low-density lipoprotein receptor and takes part in the transport of cholesterol and 
phospholipid between cells, resulting in growth and regeneration of peripheral and central 
nervous tissue (Tabaton, 1994). Three common alleles have been identified, APOE 2, 
APOE 3, and APOE 4, which translate into three isoforms3 of the protein: $2, $3, $4 
(Chai, 2007). Various combinations of any two of these alleles result in one of six 
possible genotypes: APOE 2/2, 3/3, 4/4, 2/3, 4/3 and 2/4. The APOE $3-allele is the most 
common one in the general population indicating its neutral role in AD (Serretti et al., 
2005). APOE $2 allele on the other hand is relatively rare and seems to have a protective 
role in AD, decreasing the risk and delaying age of onset (after 90 years of age) (Berlau et 
al., 2007; Corder, et al., 1994). The APOE $4 allele has been linked with AD and severe 
memory loss in various studies (e.g. Corder et al. 1993; Rose and Saunders, 1997). 
Studies have shown that the $4 allele is over-represented in AD patients, being around 
40% but only 15% in the general population (Corder, et al, 1994; Saunders et al, 1993). 
                                                
2 A#: amyloid beta, a peptide of 39-43 amino acids and is the main constituent of amyloid plaques in the 
brains of AD patients. Discussed in more detail in the following pathological chapter. 
3 A version of protein with only small alteration to another isoform of the same protein. 
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The effect of the $4 allele seems to be dose dependent in both familial and sporadic AD. 
The risk increases from being 2 to 3 fold when one $4 allele is evident, compared to 
having none, to being 5 fold when having two copies. The magnitude of this association 
can vary both with age, sex and ethnicity (Corder et al. 1993). The APOE gene itself is 
not appropriate for pre-symptomatic testing useable for the A#PP, PS1 and PS2 genes 
because not all $4 allele carriers develop AD and $4 allele linkage is not limited to AD 
alone. Even though more than half of all AD patients do not have the APOE $4 allele it 
still remains the most important risk factor in elderly individuals (Rogaeva et al., 2006). 
It is evident that the genetic mapping of AD, particularly the late-onset type, is far 
from over and it has been pointed out that approximately 70% of AD’s genetic map 
remains obscure (Lage, 2006). A number of interesting studies is currently underway to 
shed further light on the field (see review in Serretti et al., 2005). The findings with the 
most significant prospects are the discovery of the loci associated with late-onset AD on 
chromosomes 9, 10 and 12 (Pericak-Vance et al., 1997) and lately on chromosome 2 and 
15 using genetic analysis (Scott et al., 2003). Even though these findings are promising, 
none has yet been clearly established as an AD risk factor (Serretti et al., 2005). 
 
  
4.5.2 Age and gender 
It is apparent from the epidemiology studies above that the risk of developing AD rises 
significantly with age. Another possible risk factor which has caused great controversy, 
despite years of research, is whether men and women differ in the risk of developing AD 
(Barnes et al., 2005). Studies have reported mixed results with many showing a greater 
risk for women (Andersen et al., 1999; Fragtiglioni, Viitanen et al. 1997, Fragtiglioni, 
Launer et al., 2000; Gao, Hendrie, Hall, and Hui, 1998; Jorm and Jolley, 1998; Letenneur 
et al., 1999; Hy and Keller, 2000; Miech et al., 2002), while others fail to show any 
difference between the sexes (Ganguli, Dodge, Chen, Belle, and DeKosky, 2000; Herbert, 
Scherr, McCann, Beckett, and Evans, 2001; Ruitenberg, Ott, van Swieten, Hofman, and 
Breteler, 2001). Only one study found men to be at greater risk than women for 
developing AD (Lobo, Saz, Marcos, Dia, and De-La Camara, 1995). Several possible 
explanations have been put forward to account for the inconsistency in findings. One such 
states that women tend to live longer and therefore reach ages were AD is more common, 
rather than there being sex-specific risk factors. For similar reasons number of older men 
may lack, making it difficult to account for the confounding effect of age (Herbert et al., 
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2001). It has also been pointed out that women and men differ in respect to education, 
occupation and related life style variables that are associated to AD. It is possible that 
these variables are not fully accounted for in statistical analysis, and the same may be true 
of other methodological factors such as diagnostic accuracy (Barnes et al., 2005). 
Contrary to these suggestions, research on sex differences related to mortality rate and 
behavioral problems has suggested that the underlying mechanism for AD may be 
different in men and women (Ott, Lapane, and Gambassi, 2000; Gambassi et al., 1999; 
Lapane et al, 2001). In the few studies related to pathology of AD in women and men, the 
majority found no difference between the sexes (Ghebremedhin et al., 2001; Sandberg et 
al., 2001). Barnes and colleagues (2005) however found women to have a slightly more 
global AD pathology than men. 
 
 
4.5.3 Education 
Low levels of education have been associated with an increased risk of developing AD in 
multiple studies (Anttila et al., 2002; Evans et al., 1997; Fitzpatrick et al., 2004; Ganguli 
et al., 2000; Geerlings, Schmand, Jonker, Lindeboom, and Bouter, 1999; Karp et al., 
2004; Letenneur et al., 1999; 2000; Lindsay et al., 2002; Ott et al., 1999; Stern et al., 
1994), but not all (Cobb, Wolf, Au, White, and D’Agostino, 1995; Schmand, Smit, 
Geerlings, and Lindeboom, 1997; Wilson et al., 2002; Yoshitake, et al., 1995). A recent 
study conducted by Ngandu, and associates (2007) gives support to what seems to be the 
common notion that a low educational level is related to the increased risk of AD. 
According to their report, participants with medium education (6 to 8 years) had 50% 
lower risk of AD, and those with high level of education (9 years or more) had 85% 
decreased risk of developing AD, when compared to the low education group (5 years or 
less. A common explanation for theses findings is that those with higher educational level 
have more “cognitive reserve” and therefore tolerate a higher burden of pathological 
changes, thus delaying the onset of the clinical presentation (Borenstein, Copenhaver, and 
Mortimer, 2006; Stern, 2002). In line with this theory many studies have shown that 
people with higher education experience a faster rate of cognitive decline than those with 
less education (Amieva et al., 2005; Mortimer, Ebbitt, and Jun, 1991; Rasmusson, 
Carson, Brookmeyer, Kawas, and Brandt, 1996; Scarmeas, Albert, Maly, and Stern, 2006; 
Stern, Albert, Tang, and Tsai, 1999; Teri, McCurry, Edland, Kukull, and Larson, 1995; 
Unverzagt, Hui, Farlow; Hall, and Hendrie, 1998; Wilson et al., 2004). Others have found 
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a slower decline for those with higher education (Fritsch, McClendon, Smith, and 
Ogrocki, 2002), and some findings indicate that the relationship between education and 
cognitive decline is unclear or that education has no effect on the rate of decline (Filley, 
Brownell, and Albert, 1985; Haxby, Raffaele, Gillette, Schapiro, and Rapoport, 1992; 
Katzman et al., 1988; Wilson et al., 2000). It has been suggested that other variables 
confound the education-AD relation. These variables include, differences in 
socioeconomic, vascular, or lifestyle characteristics (see in Borenstein et al., 2006). Other 
recent studies undermine these suggestions, indicating the independence of the 
educational effects from other possible risk factors for AD (Ngandu et al., 2007). It is 
apparent that although the effects are to an extent contested, education has to be taken 
into account when assessing AD, not least because neuropsychological tests have been 
shown to be highly sensitive to educational variables. If education is not properly 
controlled for when assessing possible AD, it might influence the ease with which the 
diagnosis is given (Lopera et al., 1997). 
 
 
4.5.4. Traumatic brain injury 
Traumatic brain injury (TBI) refers generally to injury involving the brain and can be 
both closed head injury where the skull is intact or open head injury where the skull and 
the dura are penetrated. A specific definition of TBI is lacking within the literature 
(Lezak, 2004). The role of TBI as a risk factor in AD is highly debated and studies have 
reported mixed results (Mortimer, French, Hutton, and Scuman, 1985; Szczygielski et al., 
2005). Numerous studies have been conducted on the subject and some have found no 
connection between TBI and AD (Broe et al., 1990; Mehta et al., 1999), whereas others 
have (Gotlieb, 2000; Graves et al., 1990; Lye and Shores, 2000; Mortimer et al., 1991; 
Rasmusson, Brandt, Martin, and Folstein 1995). In particular three recent studies have 
given strong support to this interrelation (Fleminger, Oliver, Lovestone, Rabe-Hesketh, 
and Giora, 2003; Jellinger, 2004; Plassman et al., 2000). Fleminger and associates (2003) 
conducted a retrospective meta-analysis confirming the findings of Mortimer and 
colleagues from 1991. Both these studies were based only on clinical studies where the 
exact nature and severity of the original head injury were not considered. In Plassman and 
associated (2000) and Jellinger (2004) medical records were used as well as autopsy 
records in the latter study. However, results were still similar to those garnered in the 
clinical studies. According to these two studies, the risk of developing AD increases with 
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the severity of the head injury and those individuals lacking the ApoE4 allele are at the 
greatest risk of developing AD after a TBI. Contrary to the findings of Fleminger and 
associates (2003) and Mortimer and colleagues (1991), who reported men to be at higher 
risk of developing AD after TBI, no difference between the sexes was found (Plassman et 
al., 2000; Jellinger, 2004). 
 
 
4.5.5. Other potential risk factors 
Low levels of estrogen in postmenopausal women have been associated with increased 
risk of developing AD (Cunningham et al., 2001). Some studies have even maintained 
that estrogen replacement therapy could decrease the risk of developing the disease 
(Steffens et al., 1999; Tang et al., 1996; Waring et al., 1999). In accordance with these 
findings, Manly and associates (2000) reported lower levels of estrogen subtypes in 
women with AD who were not receiving hormone replacement therapy than in women in 
a control group. Other studies, such as Cunningham and colleagues 2001, have found 
higher levels of estrogen subtypes in AD patients and some have not found any benefits 
of estrogen replacement therapy (Connor and Silverstein, 1993; Matthews, Cauley, Yaffe, 
and Zmuda, 1999). In a recent study by Shumaker and associates (2004) for the Women’s 
Health Initiative Memory Study Investigators (WHIMS), the authors don’t recommend 
the use of hormone therapy for the prevention of AD or cognitive decline in women over 
65 years of age. If anything, their report indicated an increased risk of developing the 
disease by using such therapy (Shumaker et al., 2004). 
 Various early-life risk factors have been proposed such as perinatal conditions, 
early-life brain development, early-life body growth and early-life socioeconomic 
conditions. Some studies have found correlation between these variables and increased 
risk of developing AD, but others have not (see in Borenstein et al., 2006). 
 The effect of smoking on AD has been studied extensively, given that smoking is 
a risk factor for many other age related chronic diseases such as stroke. Findings are 
unclear with older case-control studies indicating a protective affect against AD while 
more recent prospective cohort studies imply unchanged or increased risk for developing 
AD (Reitz, den Heikern, van Duijn, Hofman, and Breteler, 2007). 
Other factors have come under scrutiny as possibly increasing the risk of 
developing AD and many studies are currently underway on factors such as depression, 
as well as cerebrovascular risk factors such as obesity in midlife, physical activity and 
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stroke (Honig et al., 2003; Kivipelto et al., 2005; Ownby, Crocco, Aceyedo, John, and 
Lowenstein, 2006; Rovio et al., 2007; Wilson, et al., 2002). Future research will 
hopefully decide if these factors are independent risk factors or simply comorbidities 
(Mayeux, 2006). 
 
 
4.6. Neuropathology of AD 
The brains of Alzheimer’s patients manifest two characteristic lesions as discovered by 
Alzheimer a century ago. These lesions are extracellular amyloid plaques and intracellular 
neurofibrillary tangles (Alzheimer, 1907; Emilien et al., 2004). Amyloid plaques, also 
known as senile plaques, are extracellular products that consist mainly of amyloid 
material. Amyloid is a term generally used for a group of biochemical heterogeneous 
proteins apparent in various diseases and tissues. One of these proteins is the Amyloid 
precursor protein (APP), which normally seems to play an important role in the growth 
and survival of neurons (Reinhard, Hébert, and Strooper, 2005; Saitoh and Mook-Jung, 
1996). APP undergoes various different proteolytic cleavages but in Alzheimer’s disease 
cleavage seems to take place at the wrong segment during metabolism. This leads to the 
production of an undesirable and toxic fragment beta-amyloid (# –amyloid), that 
accumulate into plaques that destroy the ability of neurons to interact (Andreasen, 2004; 
Munoz and Feldman, 2000; St Goerge-Hyslop and Petit, 2004). Three types of amyloid 
plaques have been recognized in the brains of AD patients and were originally classified 
by Wisniewski and Terry in 1972, in accordance with their maturation (see in Mann, 
1985). First are diffuse or “primitive” plaques that consist of no or small amount of 
amyloid core and have no associations with dystrophic neurites or glia (Mann, 1985). 
Symptoms of AD are not evident at this stage (Serretti et al., 2005). Next are the neuritic 
or “mature” plaques which are the classical amyloid plaques with a dense amyloid core 
intermingled with swollen neuritis, astrocytic processes and microglia (Mann, 1985). 
These irregular plaques vary in size ranging from 10 to around 200 µm in diameter and 
contain other proteins than APP, such as APOE, tau protein a1 –antichymotrypsin, 
glycosaminoglycans and transmitter-related enzymes (Serretti et al., 2005). Lastly there 
are the “burnt out plaques” which consist almost entirely of isolated amyloid core and 
high density of astrocytic and microglia cells (Mann, 1985). Neuritic plaques are 
commonly seen throughout the cortex with the heaviest deposits found in the cerebral 
cortex and thereafter the hippocampus and to a lesser degree in midbrain and subcortical 
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structures such as the corpus striatum, amygdala, and thalamus (Braak and Braak, 1991; 
Geula, 2000) 
The other hallmarks of AD, nerurofibrillary tangles (NFT), are large abnormal 
fibers found in the neurons of affected brain regions in AD patients. NFT contain 
numerous paired helical filaments (PHF), which are pairs of filaments wound in a helical 
manner (Mann, 1985). The main component of PHF is the abnormally phosphorylated 
microtubule-associated protein tau, that was discovered in 1986 by several research 
groups simultaneously (Grundke-Iqbal, Iqbal, Quinlan et al., 1986, Grundke-Iqbal, Iqbal, 
Tung et al., 1986; Ihara, Nukina, Miura, and Ogawara, 1986; Kosik, Joachim and Selkoe, 
1986; Wood, Mirra, Pollock, and Binder, 1986). In healthy neurons the fundamental role 
of normally phosphorylated tau is in neurite outgrowth and stabilization mainly involving 
microtubule dynamics. The microtubules transport substances such as nutrients and 
molecules from the nerve cell body to the end of the axon. In AD the abnormally 
phosphorylated tau seems to disrupt these transportation routes due to the PHF and its 
filaments helical nature, causing neuronal dysfunction and degeneration (Johnson and 
Jenkins, 1999, Serretti et al., 2005). What causes or generates this abnormal 
phosphorylation of tau and its extension in the brain remains unknown, but APP 
dysfunction seems the likeliest candidate (Deacourte, 2006). 
The distribution of the NFT in not diffuse, like in the amyloid plaques, but rather 
architectonic with little inter-individual variations starting at limbic structures and ending 
in the neocortical association areas (Delacourte, 2006). The consistency of this pattern 
has lead to the distinction of stages both from a neuropathological approach by Braak and 
Braak (1991) and from a biochemical one put forward by Delacourte and associates in 
1999 using the tau protein as a biomarker. Total agreement is apparent between these two 
distinctions regarding the pathway of progression of the degenerating process on NFT in 
AD (Delacourte, 2006). For practical reasons Braak and Braak propose three general 
stages with each stage having a mild and severe version. They also included the clinical 
symptom of AD but various studies have shown a positive correlation between NFT 
density and severity of cognitive impairment (Berg et al., 1998; Delacourte et al., 1999, 
Giannakopoulos et al., 2000; Munoz and Feldman, 2000). The first stage is the 
transentorhinal stage which most likely constitutes the preclinical phase of the disease 
when clinical symptoms are not evident. At this stage mild to severe pathology in the 
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transentorhinal regions4 is evident along with possible mild neuronal changes in the CA1
5 
cells of the hippocampal region. Next is the limbic stage, which possibly corresponds to 
the clinically incipient AD, where both the transentorhinal and entorhinal regions are 
heavily affected, whereas hippocampal damage is mild to moderate. The damage to the 
isocortex is still limited but scattered tangles may be evident in the basal regions of the 
fontal, temporal, and parietal lobes. The final stage is the isocortex stage where fully 
developed AD is evident. This stage is characterized by the isocortex being devastatingly 
affected as well as the extrapyramidal system. Previously affected regions have at this 
stage become even more damaged with increasing number of “ghost tangles” being 
evident (Braak and Braak, 1991). In their report Braak and Braak (1991) describe the 
third marker of AD as the neuropil threads, which are abnormal threads closely 
correlated with the NFT distribution. 
Despite the numerous studies conducted regarding AP and NFT, considerable 
uncertainty still remains. Firstly, it is still unclear whether AD develops from the AP and 
NFT or if they are merely by-products of the disease (Andreasen, 2004). Studies of intact 
individuals versus AD patients have revealed the existence of AP and NFT in both groups 
but to a lesser degree in the intact individuals, and with a more restricted distribution 
(Haroutunian et al., 1999; Munoz and Feldman, 2000; Snowdon, 1997; Snowdon et al., 
1996; Wang and Munoz, 1995). This is evident with NFT found in healthy individuals, 
which are largely restricted to the entorhinal formation and the hippocampal area 
(Delacourte et al., 1999; Haroutunian et al., 1999). In AD patients below the age of 70, 
both plaques and tangles are strongly associated with the disease (Lezak, 2004). Another 
matter of debate relates to the question of which of the two, plaques or tangles, is the 
essence of the disease (Delacourte, 2006). It has been suggested that due to the fact that 
NFT composed of altered tau occur in other disorders (e.g. Kuff’s disease and progress 
supranuclear palsy) without the presence of A# deposition, they should be seen as being 
secondary to AP in AD (Emilien et al., 2004). In line with this view is the fact that dense 
accumulations of AP have not been found in other neurodegenerative disorders and they 
seem to appear earlier than the NFT (Hardy and Allsop, 1991; Selkoe, 1991). This 
manifestation echoes the amyloid cascade hypothesis, which is a dominant causal theory 
of AD put forward in 1992 indicating that neuronal dysfunction is caused by amyloid 
                                                
4 Located between the enthorhinal regions proper and the adjoining temporal cortex. 
5 The hippocampus is divided in to four areas CA1, CA2, CA3, and the CA4   based on differences in the 
architecture of the pyramidal cell layers. 
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toxicity (Hardy, 2006). Even though today the majority of scientists agree that APP 
dysfunction plays a very important role in the etiology of AD, current research indicates a 
more complicated explanation (Delacourte, 2006). Firstly, NFT in AD have a strong 
correlation with the severity of various impairments apparent on neuropsychological tests 
such as apraxia, visual agnosia, disorientation and semantic memory. Plaques on the other 
hand have not shown any correlation to neuropsychological deficits or clinical severity in 
AD (Arriagada, Gowdon, Hedley-Whyte, and Hyman, 1992; Giannakopoulos et al., 
2000). Furthermore, a tangle-only variant of AD (5-10% of all clinically diagnosed cases) 
where no AP is evident in the brain, only NFT in the limbic/paralimpic areas, refutes 
previous findings. In line with these findings, Delacourte and associates (2002) reported a 
spatial mismatch in cortical brain areas between APP and tau pathologies, thus refuting 
the solitary role of extracellurlar A# toxicity. 
The pathology of AD does not seem to be one of pure A# toxicity or pure 
tauopathy, rather it would appear to be a combination where dysfunctional APP fuels the 
tauopathy leading to AD (Delacourte, 2006). Formation of tangles in the medial temporal 
structures could possibly be an ever-present accompaniment of aging but the presence of 
neocortical AP indicated AD. Mounting formation of tangles as a function of increasing 
dementia severity could be regarded as a determinant of the clinical progression of AD 
(Emilien et al., 2004). 
Another characteristic in AD pathology, accompanying the amyloid plaques and 
the NFT, is nerve cell and synapse loss, which leads to progressive brain atrophy 
(Cummings and Benson, 1983). Neuronal loss is more evident in the larger neurons of the 
cortex with the result that communications, metabolism and repair process of nerve cells 
are disrupted. Younger AD patients seem to be more severely affected than those 
acquiring the disease in their later years (Cummings et al., 1998). Numerous studies 
conducted postmortem (Braak and Braak, 1991; Gregory, Macdonald, Schofield, and 
Halliday, 2006), with volumetric MRI (Devanand, et al., 2007; Fox et al., 1996; Jack et 
al., 1997; 1999; 2000; Juottonen, et al., 1998; Xu et al., 2000), and most recently fluid-
registered serial MRI studies (Fox et al., 2001; Scahill, et al., 2002; Ridha et al., 2006) 
suggest the medial temporal lobe structures, particularly the hippocampus and the 
enthorhinal cortex, as the earliest sites of change in AD. As the disease progresses the 
atrophy spreads from the temporal and limbic cortices to the frontal and occipital regions 
of the brain, sparing mostly the sensorimotor cortices. This progressive atrophy correlates 
with the declining cognitive status of the patients (Thompson et al, 2003). The rate of 
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brain atrophy in AD patient has been shown to increase before the onset of any symptoms 
and to be significantly different from normal brains up to 3 years before diagnosis (Fox 
and Schott, 2004; Ridha et al., 2006). In line with the brain volume lost, AD patients have 
been found to have enlarged cerebrospinal fluid spaces compared to normal individuals 
(Scahill et al., 2002). Even though cerebral atrophy is a typical characteristic of AD, it 
does not yet distinguish normal aging from AD accurately enough to be diagnostic (Fox 
and Schott, 2004). 
Research on the pathology of AD and the earliest clinical symptoms of the 
disease, memory loss, show the significant involvement of the hippocampus. The 
hippocampus is one of the first structures to be affected by tangles and neuronal loss, 
which limits its outflow of information to other areas of the brain. When other structures 
related to the hippocampus are affected, such as the entorhinal cortex, the hippocampus 
main cortical input source, the hippocampus becomes isolated (Geula, 1998). In line with 
this, studies have shown that the extent of damage or isolation of the hippocampus is 
highly correlated with the impairment on neuropsychological functions, such as delayed 
memory (Fox et al., 1996; Villareal and Morris, 1998). Other areas affected relatively 
early in the disease are the posterior medial parietal lobes, particularly the precuneus and 
the posterior cingulate. The precuneus has been associated with episodic memory, the 
linking of new information to previous knowledge and autobiographical memory 
retrieval. The posterior cingulate on the other hand has mutual connections with both the 
hippocampal and the entorhinal cortices. Atrophy to these two structures could for these 
reasons contribute to some of the memory deficits in early AD (Scahill, et al., 2002). The 
cortical cholinergic system, originating from neurons within the basal forebrain, is 
another system involved in the neural processing of memory (Cummings et al., 1998). 
The system operates in a diffuse manner, stimulating virtually the entire cortical mantle, 
and setting the general state of the cortical neuron circuitry. In AD brains these neurons 
and their axons have been found in low densities in early stages of the disease, especially 
within the temporal lobes including the entorhinal cortex and the hippocampus (Geula, 
1998). In almost all AD brains, large bundles of NFT have been found within the 
cholinergic neurons and furthermore the cortical cholinergic making it vulnerable to the 
pathology of AD (Perry et al., 1981). 
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4.7. Neuroimaging and electro physiology of AD 
The pathology of AD has been extensively tracked with brain imaging technology as is 
evident from the previous chapter. The stereotypical limbic to frontal sequence of the 
disease has been fully recognized with the assistance of MRI, PET, SPECT, EGG, MEG 
and post mortem research (Thompson et al., 2007). In recent years the purpose of 
neuroimaging and electrophysiological techniques has moved away from diagnosis of 
advanced AD to the diagnosis of very early AD at a MCI or presymptomatic stage, 
prediction of conversion from MCI to AD and differential diagnosis from other 
degenerative diseases (Matsuda, 2007a,b; Prichep, 2007). This has increased the clinical 
and economical utility of brain imaging technology, which is reflected in the augmented 
use of imaging as a biomarker for therapeutic efficacy in AD (Rossini, Rossi, Babiloni, 
and Polich, 2007). Furthermore, advantages in instrumentation have made possible 
investigations not only of structural and functional alterations in cortical but also 
subcortical areas with high spatial resolution (Matsuda, 2007 b). 
 Research using EEG and MEG has established an increase in delta bands but a 
decrease in beta and alpha bands indicating a decreased activation of the brain, which 
seems to escalate as the disease processes (Babiloni et al., 2004; Jeong, 2004; Prichep, 
2005). Researchers have pointed out that these changes in EEG might aid in in 
discriminating between different dementia diagnosis. An example would be the strong 
decline in posterior low alpha sources, which seems specific to AD compared to vascular 
dementia and normal elderly individuals (Babiloni et al., 2004). Electrophysiological 
features have also been shown to be predictive of future decline both in MCI and AD, as 
well the likelihood of conversion there between (Huang, Wahlund, Dierks, Julin, 
Winblad, and Jelic, 2000; Jelic et al., 2000). 
 SPECT and PET studies on patients with probable or definite AD show abnormal 
bilateral decrease of regional CBF in the parietal, temporal and cingulate regions. As the 
disease progresses, abnormally low prefrontal, occipital, and whole brain levels have 
been found while the visual, sensory and the motor cortices are relatively well perfused 
until the very severe stages of AD (Rapoport, 1997; Reiman et al., 1996). With respect to 
early diagnosis of AD, a decrease in both regional CBF and glucose metabolism has been 
found in the posterior cingulate cortex and precuneus (Minoshima et al., 1997; Kogure et 
al., 2000). Presence of hypoperfusion in the parietal association areas has been reported 
as predicting rapid conversion from MCI to AD (Chetelat et al., 2003; Mosconi et al., 
2004). Many studies have shown the effectiveness of PET and SPECT to differential 
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diagnosis of AD from other types of dementia (see in Matsuda, 2007b). One of the most 
promising developments related to imaging technology is the recent arrival of PET tracer 
compounds. These pet tracer compounds enable the visualization of amyloid plaques and 
NFT, which are the hallmarks of AD in the living brain. Many believe that these traces 
will make it possible to track AD before it becomes clinically detectable, but whether that 
will be accomplished still remains to be seen (Shoghi-Jadid, et al., 2002; Small et al., 
2006). 
 With respect to MRI studies, the main focus has been on the medial temporal 
structures given the fact that AD pathology seems to emerge first in that area. Three main 
methods are generally used in connection to MRI imaging; 1) volumetric measures of 
specific structures such as the hippocampus; 2) image processing techniques where rates 
of whole brain atrophy are estimated as an percentage of volume loss per year; 3) map-
based techniques, providing 3D profiles of group differences in for instance gray matter 
loss or white matter integrity (Thompson et al., 2007). These techniques have provided 
evidence of 25% volumetric reduction of the hippocampus in patients having mild AD 
and 11% in those diagnosed as MCI (Callen, Black, Gao, Caldwell, and Szalai, 2001; De 
Santi et al., 2001; Du et al., 2001). Hippocampal atrophy has also been used to predict 
conversion from MCI to AD, with many studies finding relatively strong association there 
between (Jack et al., 1999; Killinany et al., 2002; Laakso, Halikainen, Hanninen, 
Partanen, and Soininen, 2000; Visser et al., 1999). Abnormally accelerated structural 
changes, mainly in the hippocampus and the entorhinal cortex, have also been reported in 
patients carrying the APOE $4 allele (Cherbuin, Leach, Christensen, and Anstey, 2007; 
Thompson et al., 2007). Other brain structures such as the entorhinal cortex, inferior and 
middle temporal gyri, posterior cingulate and the precuneus have been found to have loss 
in volume in MCI patients, but all these structures show deficits in mild AD (Chetelat et 
al., 2002; Xu et al, 2000; see in Thompson et al., 2007 for an extensive review). 
 Despite the great forward strides made with imaging technology, there still 
remains the fact that atrophy changes and their extent, both in AD and MCI patients as 
well as nondemented elderly individuals, can vary greatly between individuals. 
Furthermore, gross pathological similarities between AD and other dementias have been 
reported, as well as cases of mixed dementia (Ettlin et al., 1989). Finally, neither glucose 
metabolism reductions nor regional atrophy are specific to AD, which makes them 
secondary rather than primary evidence for AD (De Leon et al., 2007). For these reasons, 
relying solely on neuroimaging and electrophysiological techniques is limited but when 
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combined with neuropsychological studies, high diagnostic accuracy has been reported 
(Laakso et al., 2000; Zamrini, De Santi, and Tolar, 2004). 
 
 
4.8. Therapeutic interventions in AD 
In spite of the great need and substantial advance made in the treatment of AD, there is 
still no cure available for the disease (Farlow and Cummings, 2007). Currently, the main 
purpose of drug therapy is to provide temporary improvement, stabilization and as much 
decline of cognitive, functional, and behavioral symptoms as possible (Desai and 
Grossberg, 2005). 
From a pharmacological perspective, cholinesterase inhibitors (ChEIs) and the N-
methyl-d-aspartate (NMDA) receptor antagonist provide the most clinically relevant 
benefits and have been approved by the United States Food and Drug Administration 
(Farlow and Cummings, 2007). According to the cholinergic hypothesis, a loss of neurons 
in the basal forebrain nuclei decreases the production of the essential synthetic enzyme 
choline acetyltransferase responsible for the manufacturing of acetylcholine (ACh). ACh 
is a neurotransmitter known to be involved in memory, attention and cognition (Snyder, 
1996). Reduced levels of ACh in the brain lead to a widespread deficiency in the 
cholinergic system, which is associated with AD (Cummings, 2001). ChEIs work by 
inhibiting the acetylcholinesterase (Ache) and butyrylcholinesterase (BuChE) enzymes 
responsible for the elimination of ACh, increasing temporarily the cholinergic 
transmission in the brain (Mesulam et al., 2002). Clinically, ChEIs such as donepezil, 
rivastigmine and galantamine have been demonstrated to have beneficial effects on 
global, neuropsychologic, behavioral, and functional activities of daily living of mild-to-
moderately affected AD patients (Raskind, Peskind, Wessel, and Yuan, 2000; Rogers, 
Farlow, Doody, Mohs, and Freidhoff, 1998; Rosler et al., 1999; Wilcock, Lilienfeld and 
Gaens, 2000). The beneficial effects of ChEIs have been shown to decrease the longer 
treatment is delayed (Farlow, Anand, Messina, Hartman, and Veach, 2000; Raskind et al., 
2000). Placebo controlled trials on the other hand have demonstrated that these effects 
can be sustained for at least one 1 year and thereafter decline more gradually than with no 
treatment (Farlow et al., 2000; Lopez et al., 2005; Raskind et al., 2000; Raskind, Peskind, 
Truyen, Kershaw, and Damaraju, 2004; Winblad et al., 2001). Although the primary use 
of ChEIs is for mild-to-moderate stages of AD, there have been studies reporting 
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beneficial effects during more severe stages of the disease (Burns, Spiegel, and Quarg, 
2004; Cummings, Koumaras, Chen, and Mirski, 2005; Feldman et al., 2001). 
Another neurochemical implicated in AD is glutamate, the main excitatory 
neurotransmitter in the brain (Orrego and Villanueva, 1993). Glutamatergic 
overstimulation in the brain can lead to excitotoxicity, causing neuronal damage due to 
calcium overload within the neuron (Reisberg et al., 2003). Glutamate is known to 
stimulate a variety of postsynaptic receptors such as the N-methyl-d-aspartate (NMDA) 
receptors highly implicated in memory and furthermore the pathogenesis of AD (Farber, 
Newcomer, and Olney, 1998; Shimizu, Tang, Rampon, and Tsien, 2000). The most 
widely used NMDA receptor antagonist is memantine, which has been demonstrated to 
slow down the rate of cognitive and functional decline at the moderate-to-severe stages of 
AD (Danysz, Parsons, Möbuis, Stöfler, and Quack, 2000; Reisberg et al., 2003). Its 
effects were reported to have been retained for up to 24 weeks (Reisberg et al., 2006). 
The currently available drugs for AD do not seem to have any modifying effects 
on the disease but rather merely symptomatic benefits. In the search for modifying 
interventions, antiamyloid treatment is now the most active area of research (Desai and 
Grossberg, 2005). One such area is the investigation of antioxidants as an AD prevention 
strategy due to the fact that production of free radicals and oxidative stress6 is involved in 
the pathogenesis of AD (Christen, 2000). Antioxidants agents such as vitamin E, C and 
Ginko biloba have been studied with mixed results. Some studies have reported evidence 
of efficacy but others have shown either inconsistent results or no efficacy at all (see in 
Ancelin, Christen, and Ritchie, 2007). Further research regarding these supplements is 
needed with emphasis on randomized prevention trials (Zandi et al., 2004). Another weak 
antioxidant agent is estrogen; giving rise to the possibility that hormone replacement 
therapy could serve as a protective factor against cognitive decline and AD (Manly et al., 
2000). Recent studies have refuted such claims with some even proposing increased risk 
of developing AD (Shumaker et al., 2004)  
 Several epidemiological studies have reported lower incidences of AD with 
individuals taking non-steroidal anti-inflammatory agents (NSAIDs) on long-term basis 
(Landi et al., 2003; Szekely et al., 2004; Zandi et al., 2002). Effects of NSAIDs seem to 
be limited to decreasing the risk of AD, but not its progression (Standridge, 2004). The 
                                                
6 Oxidative stress occurs when the body's antioxidant defenses are unable to cope with the free radical 
attacks and oxidation reactions taking place in the body (Christen, 2000). 
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exact levels of NSAIDs dosage necessary for efficacy are still unclear with studies 
showing mixed results (Broe et al., 2000). In light of the fact that appropriate dosage, 
duration of intake and the risk ration of possible undesirable side affects are still not 
known, most researchers don’t recommend the use of NSAIDs in AD (Etminan, Gill, and 
Samii, 2003: Standridge, 2004). 
  Discoveries and reports (Dodart et al., 2002, Solomon, Koppel, Hanan, and 
Katzav, 1996) of a new vaccine that blocks AD in genetically engineered mice and 
reduces the helical form of amyloid plaques lead to the trial of A# vaccination in AD 
patients (Morgan, 2006). Even though the results of the trials were promising in respect to 
the slowing of cognitive decline and reduction of amyloid plaques (Hock et al., 2003; 
Nicoll et al., 2003), they were cut short due to serious side effects of the vaccine 
(Orgogozo et al., 2003). These observations have however accelerated the development 
of a safer vaccine that might offer promising results in the future (Morgan, 2006). 
 Although early interventions are central in the treatment of AD patients, handling 
symptoms developing as the disease progresses is also important (Desai and Connor, 
2005). Behavioral disturbances such as agitation, psychosis, depression, anxiety and 
insomnia are common and treatable with antipsychotics; risperidone and olanzapine or 
other relative agents (Cummings, 2001; Herrman and Lanctot, 2007; Rocca, Marino, 
Montemagni, Perrone, and Bogetto, 2007). Approaches such as cognitive training and 
cognitive rehabilitation have led to mixed results and need further research (Clare and 
Woods, 2004; Davis, Massan, and Doody, 2001). Last but not least, ensuring the long-
term well being of the patient’s caregivers is of the outmost importance. They spend 40-
100 hours a week with the patients and many experience emotional, social and physical 
difficulties and hardships, as well as financial losses (Bullock, 2004). The better the 
patient’s caregivers feel and understand the disease and their situation, the better for the 
patient himself (Desai and Connor, 2005). 
 
 
5. Neuropsychology and preclinical AD 
In the last decade, considerable evidence has been put forward indicating that individuals 
who later develop AD show cognitive deficits several years before clinical diagnosis has 
been established (Chen et al., 2001; Elias et al., 2000; Jacobs, et al., 1995; Tierney, Yao, 
Kiss, and McDowell, 2005). Knowledge concerning the preclinical stage of AD is 
extremely valuable from a theoretical as well as a clinical perspective. Theoretically, 
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understanding the transitional phase from normal aging to AD is important for further 
knowledge of the development of the disease. From a clinical perspective, identifying 
those at the most risk as early as possible maximizes the effects of available therapeutic 
interventions (Bäckman et al., 2005). The research designs used in the investigation of the 
preclinical stages of AD can be divided into two categories: a) longitudinal7 and b) cross- 
sectional designs8.  
In an early longitudinal study from 1995, Jacobs and associates administered a 
comprehensive neuropsychological test battery to initially nondemented individuals. 
Those that eventually developed AD showed early deficits on the immediate recall on the 
Selective Reminding Test, word-finding abilities on the Boston Naming Test (BNT), and 
in abstract reasoning on Similarities of the WAIS subtest. Rubin and associates (1998) 
reported findings of healthy participants evaluated annually over a 15-year period. 
According to them, reduced performance on Logical Memory was evident with those 
later showing measurable clinical changes and global psychometric deterioration. In the 
Framingham prospective community study lasting over 22 years, Elias and associates 
(2000) reported memory (measured with LM-retained) and abstract reasoning (measured 
with Similarities) to be most predictive of later AD development. According to the 
authors, these tests could predict AD after a dementia free period of as long as 10 years. 
The majority of other early longitudinal studies report similar findings with deficits on 
verbal episodic learning and memory tasks being most evident in preclinical AD, 
followed by impairments in visual memory but not as much in other cognitive domains 
(see Bäckman, Small, and Fratiglioni, 2001; Bondi, et. al., 1994; Chen et al., 2001; 
Howieson et al., 1997; Small, Fratiglioni, Viitanen, Winbld, and Bäckman, 2000; Tierney 
et al., 1996; Touchon and Ritchie, 1999; Tuokko, Vernon-Wilkinson, Weir, and Beattie, 
1991;  for an overview, see in Bäckman, Small and Fratiglioni, 2004). These measures on 
memory include story recall, learning of word lists and verbal paired associate tasks 
(Collie and Maruff, 2000), suggested by some to be particularly effective in identifying 
those at risk of developing AD (Elias et al., 2000; Small, Herlitz, Fratiglioni, Almkvist, 
and Bäckman, 1997; Tierney et al., 1996). In line with these findings structural imaging 
studies have shown that areas known to be important in episodic remembering such as the 
                                                
7 Longitudinal designs, neuropsychological test batteries are administered to a large cohort of non-demented 
elderly individuals to establish baseline to which future performance on the same tests can be compared 
(Collie and Maruff, 2000). 
8 Cross sectional design, neuropsychological performance of a group of individuals defined as high risk for 
AD is compared to a group of individuals that does not possess the same risk factor (Collie and Maruff, 
2000). 
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hippocampus and other medial lobe structures are among the first to be affected in AD, 
years before diagnosis (Chetelat et al., 2003; Fox et al., 1996; Villareal and Morris, 1998; 
Xu et al, 2000). 
 A meta-analysis by Bäckman and associates (2005) was recently conducted with 
the goal of establishing the degree of impairment in different cognitive domains in 
preclinical Alzheimer’s disease. The meta-analysis was based on 47 studies with a total of 
9097 controls and 1207 preclinical AD cases. Results from the study suggested that 
cognitive impairment in preclinical AD not only affects memory but is of a more global 
nature than previously thought (see also Arnáiz and Almkvist, 2003; Small et al., 2007; 
Traykov et al., 2007). Preclinical deficits were found in global cognitive ability, episodic 
memory, perceptual speed and executive functioning. Less severe deficits were found in 
verbal ability, visuospatial skill and attention but no preclinical deficits were found in 
primary memory. Despite the global nature of the impairment, memory, as in the earlier 
studies, remained the cardinal feature of pending dementia disease but its previously 
unique status has now been cast in doubt. Within the domain of episodic memory, the 
analysis revealed that delayed recall was more efficient than immediate recall. This lends 
strength to the opinion that the main characteristic of episodic memory impairment in 
preclinical AD is inability in transferring information from temporary storage to a more 
permanent memory (Bäckman and Small, 1998; Bäckman et al., 2005). A larger effect 
size was apparent for recall than for recognition, which indicates that retrieval problems, 
in addition to encoding and consolidation, are possibly characteristics for preclinical AD. 
Finally, a larger effect size was evident for verbal than for nonverbal material (Bäckman 
et al., 2005). In the context of these findings it is interesting to note that recent brain-
imaging studies indicate that multiple brain structures and function, in addition to the 
medial temporal lobes, are affected before diagnosis of AD (Fox et al., 2001; van der 
Flier et al., 2002). Results from the meta-analysis also provided information related to the 
timeframe of cognitive deficits in preclinical AD. According to the results significantly 
less deficits were found in those individuals evaluated more than 3 years before 
diagnosis. However, some studies with longer retest intervals (up to 15 years before 
diagnosis) showed relatively large effect size, especially on global cognitive abilities and 
episodic memory. These finding concur with other studies (Bäckman et al., 200; Chen et 
al., 2001; Saxton et al., 2004; Small et al., 2000; Tierney et al., 2005) indicating relative 
stability in cognitive deficits at the onset of preclinical AD until a few years before 
diagnosis, when a more abrupt decline occurs (Bäckman et al., 2005). 
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 More recent studies focusing on the preclinical stages of AD and MCI, in 
particular the amnestic type a-MCI, given the higher than average conversion rate to AD 
(Petersen, 2004), have yielded similar results (Amieva et al., 2005; Blacker et al., 2007; 
Dickerson et al., 2007; Fleisher et al., 2007; Galvin et al., 2005; Powell et al., 2006;). In 
their longitudinal study, Fleisher and associates (2007) evaluated 539 a-MCI patients over 
a 3-year period, during which 212 patients progressed to AD. According to their results, 
progression from a-MCI to AD was best determined by a combination of four 
neuropsychological measures; the Symbol Digit Modality test, Delayed 10-Word List 
Recall, New York University Paragraph Recall Test (delayed) and the Alzheimer Disease 
Assessment Scale-Cognitive subscale (ADAS-cog). In another longitudinal study 
conducted by Tabert and associates, (2006), the conversion from MCI to AD was 
estimated as well as the optimal early cognitive markers. They also estimated which of 
the MCI subtypes constitute the most risk of progressing to AD. Their findings suggest 
that MCI patients with memory as well as another cognitive impairment are at higher risk 
of developing AD than pure a-MCI patients. Furthermore, they reported that deficit in 
verbal memory and psychomotor speed/executive functioning abilities have the strongest 
predictive accuracy of possible conversion to AD. 
 The results from Taberts and associates (2006) study contradict the common view 
that the a-MCI subgroup is at the highest risk of converting to AD and underlines the 
controversies surrounding clinical criteria of MCI. As previously discussed, number of 
individuals meeting the criteria for MCI at one point might be classified as cognitively 
healthy later on (Larrieu et al., 2002). The preclincal stage of AD on the other hand lacks 
specific clinical criteria, partially due to substantial variability in compensatory 
mechanisms and general cognitive functions among humans leading to overlapping 
performances. The performance of an individual whose general cognitive abilities are 
limited overlaps easily with someone that initially had superior cognitive abilities but is 
beginning to decline dramatically and ultimately faces AD (Small et al., 2007). 
Longitudinal studies on preclinical AD and MCI confirm the importance of conventional 
neuropsychological tests in the research and treatment of AD (Collie and Maruff, 2000; 
Bäckman et al., 2005; Powell et al., 2006; Small et al., 2007). These studies show that 
cognitive deficits apparent in AD can be identified before the disease is clinically 
diagnosed, and elderly individuals experiencing these subtle changes can be distinguished 
from those that are healthy (Collie and Maruff, 2000). 
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5.1. Familial studies 
Neuropsychological studies on individuals exhibiting AD risk factors, especially familial 
studies, have constituted a common approach to research on preclinincal AD. These 
studies have generally indicated that relatives of AD patient show impaired performance 
on neuropsychological tests sensitive to the preclinical stages of AD.  
Earlier studies focused largely on individuals with a strong family history of the 
disease, in most cases early-onset AD (Twamley et al., 2006). For instance, La Rue, 
Matsuyama, McPherson, Sherman, and Jarvik (1992) assessed the cognitive performance 
of 21 adult children and 11 siblings of patients with probable AD over a 4 -year period. 
According to their findings, relatives of patients with early-onset dementia were more 
likely to exhibit decline in performance than relatives of patients with late-onset 
dementia. In a later study, La Rue, O’Hara, Matsuyama, and Jarvik (1995) compared the 
cognitive performance of 40 first-degree (mean age around 56 years) relatives to 24 
match controls (mean age around 58 years) with no family history of dementia. Their 
results revealed that the relatives of AD patients showed greater decline on the cognitive 
measures than the control group, and furthermore that no difference was evident in 
cognitive decline between the late-onset and the early-onset relative groups. Contrary to 
these findings, Small and colleagues (1994) reported no difference in cognitive abilities 
between 29 participants having at least one first-degree relative with documented AD and 
14 without such family history (mean age around 60 years). All the participants in the 
study complained of memory difficulties. One year later, Small, La Rue, Komo, Kaplan, 
and Mandelkern (1995) conducted another study yielding similar results. In this study two 
groups of individuals were followed for approximately 3 years. 28 individuals had a 
family history of AD and 14 were without such history (mean age around 60). The groups 
were assessed with two cognitive measures, one concerning verbal memory (Buschke-
Fuld Selective Reminding Test) and one measuring visual-spatial memory (Benton Visual 
Retention Test). In agreement with the earlier study, no differences were found between 
the two groups on either of the cognitive measures. 
 In a study conducted by Hom, Turner, Risser, Nonte, and Tintner (1994), the 
neuropsychological performance of 20 asymptomatic first-degree relatives of AD 
patients, 18 adult children and 2 siblings (mean age 54,5 + 5,7 years), was compared to 
20 controls who had no family history of dementia (mean age 57,7+ 6,3 years). Their 
findings showed that the relatives performed significantly worse on several domains than 
the age, education and gender matched control group. These domains included measures 
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of verbal intelligence and short-term memory, attention and concentration. In a similar 
study, Bondi and associates (1994) assessed 46 nondemented individuals (mean age 
around 70 years) with the California Verbal Learning Test (CVLT) annually over a 3-year 
period. According to their results, individuals with a first-degree relatives of AD were 
more likely to undergo changes in diagnostic status over the 3 year period and 
performance on the CVLT predicted those later developing AD. 
Research interest in persons at risk for autosomal dominant forms of AD has 
increased in recent years, in particular the preseniliin-1 mutation (PS1) carriers, related to 
preclinincal AD. These individuals are known to be at 50% risk of inheriting the mutation 
which makes them a preferable research group (Rosselli et al., 2000). In the most 
common cases of autosomal dominant forms such as the PS1, PS2 and the APP, 
neuropathological findings have been similar to those of the sporadic form of AD, but 
with a more rapid progression as discussed above (Ringman et al., 2005). Cases of 
familial AD with atypical neuropathology have been reported (Verkkoniemi et al., 2001). 
Several groups have described neuropsychological deficits affecting individuals carrying 
the PS1 mutation. The deficits commonly found include delayed recall on both verbal and 
visual episodic memory, with executive functioning sometimes affected, most often in 
PS1 carriers (Díaz-Olavarrieta, Ostrosky-Solis, Garcia de la Cadena, Rodriguez, and 
Alonso, 1997; Fox, Warrington, Seiffer, Agnew, and Rossor, 1998; Lasprilla, Iglesias, 
and Lopera, 2003; Lopera et al., 1997; Rosselli et al., 2000; Ringman et al., 2005). These 
finding concur with findings from late-onset sporadic AD (Ringman et al., 2005). 
In a study on late-onset AD, Rice, Abraham, Rudrasingham, Owen, and Williams 
(2003) found siblings of AD patients to show significantly more impairment on overall 
memory performance. This was also evident when the siblings were grouped in 
accordance to whether they had APOE " 4 allele or not. A total of 33 siblings were tested 
(mean age of 70 years) and 22 individuals (mean age of 76 years) that had no family 
history of dementia. Even though the siblings were somewhat younger, they still scored 
significantly lower on the MMSE and premorbid IQ and were more likely to possess an 
APOE " 4 allele. When premorbid IQ and MMSE scores were controlled for, siblings 
scored more poorly than controls on overall memory measured by the Doors and People 
test. 
In line with Rice and associates, recent studies (see in Small, Rosnick, Fratiglioni, 
and Bäckman, 2004, Twamley et al., 2006) on familial AD have to a greater extent 
focused on genetic susceptibilities such as the presence of APOE " 4 allele, in addition to 
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family history, in order to enrich their pool of at-risk individuals (Bondi et al., 1994; 
Twamley et al., 2006). For instance, Caselli and associates (2004) followed a mixed 
sample of cognitively intact individuals (mean age of 60 years) who had first-degree 
relatives with AD. Of these individuals 87 were found to be APOE " 4 allele carriers, 
leaving 94 noncarriers. Multiple measures on neuropsychological tests over a 33-month 
period revealed accelerated decline among APOE " 4 allele carriers on the Auditory 
Verbal Learning Test (total learning) and long term delayed recall, as well as on the 
Selective reminding Test free and cued recall. No differences were found in other 
domains such as language, spatial skills, or executive functioning. Other similar studies 
on APOE " 4 allele carriers have been conducted, such as the NIMH Prospective Study of 
Biomarkers for Older Controls at Risk for Alzheimer’s Disease (Levy et al., 2004). 
Reports from this study also indicate subclinical deficits in verbal learning and recall 
(Levy et al., 2004) among individuals carrying APOE " 4 allele, as well as deficits in 
divided attention (Rosen, Bergeson, Putnam, Harwell, and Sunderland, 2002), and other 
subtle problems in visual attention and working memory (Greenwood, Lampert, 
Sunderland, and Parasurmaman, 2005). Two meta-analysis exploring the general effects 
of carrying the APOE " 4 allele in familial and preclinical AD studies give mixed results, 
indicating a general effect on cognitive performance, which is primarily manifested in 
verbal and visual learning, and memory. However, the effects seem to be limited and 
restricted to certain domains of cognitive performance (Small et al., 2004, Twamley et al., 
2006). 
 
 
5.2. Neuropsychological predictors of AD 
Despite the great advances made within imaging and in the pursuit of biochemical 
biomarkers for AD, neuropsychology remains the cornerstone for diagnosis and 
characterizing the cognitive impairments that take place in early AD (Bäckman et al., 
2005; Collie and Maruff, 2000; Goldman et al., 2001; Ringman et al., 2005; Small et al., 
2007; Twamley et al., 2006). As is evident from the above discussion, there is a 
consensus about memory impairments being the first signs of AD. More specifically, 
impairments in verbal and nonverbal memory and, particularly, delayed memory as 
measured on specifically designed tests (Bäckman et al., 2001; Bäckman et al., 2005, 
Bondi, et. al., 1994; Chen et al., 2001; Fox et al., 1998; Howieson et al., 1997; Jacobs et 
al., 1995; Rubin et al., 1998; Small et al., 2000; Tierney et al., 1996). More recent studies 
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have refuted the lone status of memory in preclinical AD, suggesting instead deficits of a 
more global nature (Bäckman et al., 2005; Small et al., 2007; Twamley et al., 2006). 
There still remains a lack of consensus as to the order in which the other domain 
impairments appear, although deficits in executive functions and perceptual speed seem 
to evolve before those affecting verbal ability, visuospatial skills and attention (see in 
Bäckman et al., 2005). Although much progress has been made in identifying the earliest 
cognitive markers, as well as the neuropsychological tests which are most sensitive to 
them, diagnosis of preclinical AD remains very challenging. As has been mentioned, 
establishing clear clinical criteria for this stage is very important in terms of future 
research. One area, which has gained increasing interest in recent years and might shed 
further light on the matter, is research on adult children of AD patients. Even though 
these individuals have been studied in mixed samples with other relatives, exclusive 
investigation of the cognitive development of this at risk group for AD is limited (Jarvik 
and Blazer, 2005). 
 
 
5.3. Adult children of AD patients 
The research literature in terms of cognitive decline in adult children of Alzheimer 
patients is very limited. This is surprising for the following reasons: 1) these individuals 
are at increased risk of developing the disease and therefore constitute a preferable 
research group; 2) early detection of AD before significant brain damage has occurred 
will be of the outmost importance once more effective interventions become available; 3) 
many children of AD patients spend their lives caring for their parents but are at the same 
time terrified of developing the disease themselves; 4) there is scarcity of information 
regarding the number of children of AD patients and the likelihood of them developing 
the disease (Jarvik and Blazer, 2005; Sager et al., 2005). 
Most of the information regarding this at risk group is drawn from the research 
mentioned above where siblings and adult children of AD patients are treated as one 
homogenous group (Jarvik et. al., 2004). The majority of these studies indicate that first-
degree relatives of AD patients are more likely to show decline in cognitive performance 
over time than individuals with no family history of AD (La Rue et al., 1995; Bondi et al., 
1994; Hom et al., 1994) with few exceptions (Small et al., 1994; Small et al., 1995; Díaz 
et al., 1997). 
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The only published articles found which exclusively evaluate the cognitive 
development over time of adult children of AD patients are the findings of Smalley and 
colleagues (1992), Jarvik, La Rue and associates (2005), and Ercoli, Siddarth, Harrison, 
Jimenez, and Jarvik (2005). The two latter studies were published following a 2-day 
conference held to shed light on the current status of research concerning this particular 
group. The main conclusion of the conference was that more data are needed on the 
children of Alzheimer’s patients (Jarvik and Blazer, 2005). 
The first published study focusing exclusively on children of AD patients was 
conducted by Smalley and associates in 1992. They evaluated 106 adult children (mean 
age of 40, 6 years) that had at least one parent diagnosed with AD, using the WAIS and 
several tests of learning and memory. Three memory measures were selected for the 
study on the basis of their documented sensitivity in identifying mild dementia. The 
measures selected were the Paired Associated Learning Test (PALT), Benton Visual 
Retention Test (BVRT), and the Object Memory Evaluation (OME). The results of the 
tests indicated that the adult children mean average performance was not below aged 
matched norms. However, intraclass sibling correlation indicated an isolated group that 
seemed to score lower than the rest of the children group. 
In their research, Jarvik, La Rue and associates (2005) conducted a 20-year follow 
up of the performance of 25 adult children of the original sample from Smalley and 
associates, with mean age of 62 years. Neuropsychological measures used in the research 
were eleven, including nine subtests of the WAIS, BVRT, and the PALT. The 
reassessment revealed decline on one of the neuropsychological measures used, the Digit 
symbol subtest of the WAIS, but only for the raw scores of the test and not the scaled 
scores where age is taken into account. 
Ercoli and associates (2005) worked with the same research group, the 25 
children, as Jarvik and associates did in their pilot study. Due to the lack of a control 
group in the original study, Ercoli and associates compared the 20-year old follow up 
scores with the scores of an age-comparable sample of 24 healthy individuals with no 
family history of AD. The two groups were compared on six overlapping 
neuropsychological measures which included four subtest of the WAIS (digit symbol, 
block design, vocabulary and similarities), as well as BVRT and the Mini Mental State 
Examination (MMSE). Result showed only two statistically significant differences 
between the two groups. Firstly, the control group was statistically older than the children 
group (68 vs. 62 years) and, secondly, that the children group scored significantly lower 
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than the control group on the MMSE controlling for age. Secondary analysis using a 
truncated sample, no longer differing in age, yielded the same results. 
Other researches and databases related to the children of AD patients are new and 
have at the most provided baseline assessments of cognitive performance and await 
further results in the near future. Two such studies of recent origin are the Washington 
University Adult Children study (ACS) and the Wisconsin Registry for Alzheimer’s 
Prevention (WRAP) (Jarvik and Blazer, 2005). In the ACS study, the main purpose is to 
develop and validate imaging factors, biological markers, cognitive performance and 
other indicators related to preclinical AD. By doing this, the researchers hope to provide 
ways to identify those individuals at high risk of developing the disease at the earliest 
possible stages. Two groups of individuals between the ages of 45-74 are being enrolled, 
beginning in 2004. One group is constituted of adult children with at least one parent 
diagnosed with AD while the other was made up of adult children that have parents that 
are at least 70 years old but have not been diagnosed with AD. Cognitive performance at 
baseline assessment is gathered using the MMSE. No results have yet been published 
(Coats and Morris, 2005). 
The WRAP study which has been ongoing since 2001 had in the year 2005 
completed the baseline assessment of 425 individuals with a mean age of 53 and who 
have at least one parent diagnosed with AD. Each individual was assessed with a 
comprehensive neuropsychological battery along with APOE genotyping, laboratory 
tests, clinical measurements such as blood pressure and a health history form. The 
neuropsychological battery consisted of variety of test measuring the following five 
cognitive domains: 1) intelligence, 2) language and verbal skills, 3) visuo-spatial skills, 4) 
verbal and visual episodic memory measures, and 5) working memory and executive 
abilities. The only results published so far are that children carrying the APOE 4 allele 
(n=224) scored significantly lower on the block design than those children not carrying 
the APOE 4. No other differences were evident between the two groups on the 
neuropsychological measures. According to the authors the results indicate that the APOE 
4 gene has yet to have measurable impact on the cognitive function in the WRAP sample. 
Enrollments of control participants began in 2005 and only those individuals with a 
parent unaffected by AD and 75 or older were accepted. No results regarding the control 
group have been published (Sager et al., 2005). 
 As the above discussion indicates, the findings on the cognitive development of 
adult children of AD patients are very contradictive, a fact confirmed by the general 
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opinion within the field (Twamley et al., 2006). A likely explanation is that majority of 
the studies fail to fulfill some of the methodological requirements necessary to maximize 
the reliability and validity of their results (see table 4). 
  
Table 4.  
An overview of studies conducted on adult children of AD patients. 
Degree of risk for AD Research 
group 
Controls Age  
(M) 
Neuropsychological Tests  Follow-Up 
Interval (Years) 
Studies on adult children with at least one first-degree relative  
Smalley et al., 1992 106 0 40 WAIS, BVRT,PALT, OME One measure 
Bondi, et al., 1994 28 (Mix) 25 70 MMSE,  DRS, VFT, BNT, 
WAIS-(R), TMT, CDT, CST, 
WSC, WMS-(R), BSR,CVLT 
 
3  
Hom et al., 1994 20 (Mix) 20 56 WAIS,WMS-(RR), HRCT, 
TPT, RHY, SSPT,R-IASE 
 
One measure 
Small et al., 1994 29 (Mix) 14 60 MMSE, WAIS, WMS, BNT, 
BVRT, RFT (Complex), BSR 
 
baseline 
La Rue, et al., 1995 40 (Mix) 24 57 WAIS, BVRT, OME, PALT 6 
Small et al., 1995 28 (Mix) 14 60 BSR,BVRT 1 
Coats and Morris, 2005 (ongoing) 67 CH 17 60 MMSE baseline 
Ercoli et al., 2005 25 CH 24 57 WAIS, BVRT,PALT MMSE 20 
Jarvik, La Rue et al, 2005 25 CH none 65 WAIS, BVRT,PALT 20 
Sager et al., 2005 (ongoing) 425 CH On going 53 WASI,WMS(III), AVLT, 
COWA, WRAT3, BNT, 
TMT(B), WCS, JLO 
 
Baseline 
Studies on adult children with autosomal dominant forms of AD 
Díaz et al., 1997 14 (Mix) 14 36 MMSE, WMS, RFT, BNT, VFT 1 
Fox et al., 1998 63 0 45 WAIS-(R), GNT, VOSPT, PST, 
GDAT, GDST 
6 
 
Note: WAIS, Wechsler Adult Intelligent Scale; WASI, Wechsler Abbreviated Scale of Intelligence; WMS, Wechsler Memory Scale; 
AVLT, Rey Auditory Verbal Learning Test; COWA, Controlled Oral Word Associations; WRAT, Wide Range Achievement Test, 
3rd edition; BNT, Boston Naming Test; TMT, Trail Making Test (A) (B); WCS, Wisconsin Card Sort; JLO, Judgment of Line 
Orientation; MMSE, Mini Mental State Examination; DRS, Dementia Rating Scale; VFT, Verbal Fluency Tests; CDT, Clock 
Drawing Test; CST, Clock Setting Test; BSR, Buschke Selective Reminding procedure; CVLT, California Verbal Learning Test; 
HRCT, Halstead Category Test; TPT, Tactual Perception Test; RHY, Seashore Rhytm Test; SSPT, Speech-Sounds Perception Test; 
R-IASE, Reitan-Indiana Aphasia Screening Examination; RFT, Rey-Figure Test; BVRT, Benton Visual Retention Test; OME, 
Object Memory Evaluation; PALT, Paired Association  Learning Test; GNT, Graded Naming Test; VOSPT, Visual Object and 
Spatial Perception Test; PST, Psychomotor Speed Test; GDAT, Graded Difficulty Arithmetic Test; GDST, Graded Difficulty 
Spelling Test. 
 
Firstly, most of the studies (e.g. Ercoli et al., 2005; Jarvik et al., 2005) have small sample 
sizes and, in many cases, the samples are poorly defined with, for example, siblings and 
children being grouped together without further clarification (Bondi, et al., 1994; Días et 
al., 1997; La Rue, et al., 1995; Small et al., 1994; Small, La Rue et al., 1994). Secondly, 
control groups are in some instances lacking (Jarvik et al., 2005) or are either not age or 
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education matched (Ercoli et al., 2005) which is highly important when working with 
neuropsychological tests (Lezak, 2004). Some of them only provide cross- sectional 
measurements (Small et al., 1994; Hom et al., 1994), but research has shown an 
overestimation of cognitive decline due to cohort effects in such designs (Small, 2001; 
Collie and Maruff, 2000). Finally, in several of the studies neuropsychological tests used 
are limited, with regard to numbers as well as the functional domains they measure (e.g. 
Small et al., 1995). Often, there is also lack of tests that measure memory exclusively, 
which most researchers agree is the first cognitive function to start decline in preAD. 
 Although adult children of AD patients have in recent years gained increased 
research attention, it is clear from the discrepancy in research findings that there is great 
need for well-structured, longitudinal research from which unmistakable and reliable 
results can be drawn. Results gathered from such studies could not only help better 
understand the risk, prevalence and cognitive markers related to adult children of AD 
patients, but also the early diagnosis of AD in general. 
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PART II: A NEUROPSYCHOLOGICAL REASSESSMENT ON ADULT 
CHILDREN OF AD PATIENTS: A SEVEN YEAR FOLLOW-UP 
 
 
6. Aims of the study: 
In this study subjects (AC), adult children of Alzheimer’s patients (AD), were compared 
to a group of people (NC) who had no known first-degree relatives with dementia on two 
occasions over a nine-year period. The initial assessment was carried out between the 
years 1998-2000 and the reassessment in 2007. Each group was then compared to its own 
performance at these two points in time. Participants in both groups were active members 
of the community and had no history of memory problems prior to assessment. The aims 
of this study are the following: 
 
1. To see if the adult children of AD patients show any cognitive impairment 
compared to a group of people with no first-degree relatives suffering from 
dementia. 
2. To see if the adult children of AD patients evince faster decline on any of the 
neuropsychological tests compared to the control group. 
3. To see which neuropsychological tests best differentiate the two groups. 
 
 
7. Method 
 
7.1. Subjects 
The subjects in the study were adult children of AD patients (AC) and a control group. 
The AC group was selected randomly from pedigrees of individuals with a history of 
dementia, which is connected by at lease two AD patients within six meiotic events or 
less. The NC group mainly consisted of spouses of those participating in the study, with 
the addition of a few individuals who volunteered after seeing an advertisement. The NC 
participants had no known first-degree relatives with dementia. The AC and NC group 
were assessed with the same neuropsychological tests on two occasions over a 9-year 
period. The first assessment took place between 1998-2000 and the second in 2007. 
 Of the original sample (N=210), 152 individuals were contacted randomly for the 
reassessment blind to group membership. Of theese 152 individuals 119 participated (78, 
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3%), 10 refused to participate, 6 didn’t show up for assessment and 17 couldn’t 
participate for other reasons such as geographical situation or limitation of time, given the 
narrow timeframe when the assessment took place. Of the 119 individuals that 
participated, 6 met the exclusion criteria and were left out of the statistical analysis. The 
exclusion criteria in the study were the following: Known central or peripheral nervous 
central disorders; severe psychiatric illness, significant or uncorrected impairment of 
hearing, vision, or movement, or other physical disabilities or impairment that would in 
any way affect performance on the neuropsychological test battery. 
Statistical analysis was based on 113 individuals, 83 in the AC group and 30 in 
the NC group. In respect to age, sex and education no difference was found between the 
two groups (see table 5). 
 
Table 5. 
Demographics for the AC and NC group. 
 AC group 
n = 83 
NC group 
n = 30 
Year of assessment 2000 2007 2000 2007 
Age (years)     
Average 52.2 59.1 53.8 59.9 
Standard deviation 7.0 6.8 7.1 7.0 
Range 40-68 46-74 43-66 48-73 
Sex   
Woman 49 (59%) 14 (47%) 
Men 34 (41%) 16 (53%) 
Education   
% 8 26 (31%) 8 (27%) 
>  8 57 (69%) 22 (73%) 
 
 
7.2. Material/Instrument 
The same Questionnaires and neuropsychological tests were used in both assessments 
except for three tests: the Letter Cancellation test, the Picture arrangement of the WAIS 
and the Reading and understanding test. These test were cancelled because of the limited 
discriminant validity in the original study and because they take long to administer. There 
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are no data available for the reliability and validity of the Icelandic translations of the 
neuropsychological tests used in this research. However, the original study from 1998-
2002 (Pálsson, 2002) and the English versions have shown that these tests are sensitive to 
the cognitive impairment evident in Alzheimer’s disease (Strauss, Sherman, and Spree, 
2006). 
 
The questionnaires and the neuropsychological tests were administered in the following 
order: 
 
7.2.1 Questionnaires 
Memory Observation Questionnaire. Consists of 13 questions that measure the subject’s 
perceptions of his present memory functioning. The questions are answered on a five 
point scale were 1 means “never” and 5 “always”. The total score is gathered from all the 
questions and a higher score indicates more memory complaints (McGlone, Gupta, 
Humphrey, Oppenheimser, Mirsen, and Evans, 1990) (Icelandic translation: Margrét 
Dóra Ragnarsdóttir and María K. Jónsdóttir, 1998 (unpublished)). 
 
Health questionnaire. The original questionnaire used in the first assessment consisted of 
21 questions regarding the subject’s health. Questions involving conditions such as 
central or peripheral nervous system disorders, psychiatric disorders, chronic drug or 
alcohol use and physical disabilities or impairments that are known to affect the outcome 
on neuropsychological tests. During the latter assessment, subjects were only asked for 
notable changes in their health since the prior assessment. 
 
 
7.2.2 Neuropsychological tests  
Orientation. Subject is asked to state the following: His or her name, date of birth and age 
(personal orientation); where he or she is located (street and city) during the testing 
(orientation to place); and, finally, the present year, month, day and time (orientation to 
time). 
 
Rey-Osterrieth Complex Figure. The participant copies a figure and is then asked without 
any warning to reproduce it from both immediate (30 seconds later) and delayed memory  
(45 minutes later) (Lezak, 2004; Strauss et al., 2006). 
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Wechsler Memory Scale (WMS) subtests. 
The Logical Memory (LM) of the WMS. Consist of two stories that are read to the subject 
aloud and he asked to reproduce them from immediate memory (15 seconds later) and 
delayed memory (45 minutes later). The average score of remembered items from both 
stories was used and the Gist scoring criteria to evaluate the recalled stories (Strauss et 
al., 2006). 
 
The Associate Learning Test of the WMS. The participant listens to a list of 10-word 
pairs, then one word from each pair is presented and the subject must provide the word 
that went with it. There are three trials of the list. Of the 10 word pairs six are labeled 
“easy” with clear association (give half credit) and four of them are labeled “hard” with 
no obvious association between the words (give one credit) (Strauss et al., 2006). 
 
Wechsler Adult Intelligence Scale (WAIS) subtests. 
Digit Span of WAIS forward and backwards. In digits forward, the task is to repeat each 
sequence of digits as it is given. When a sequence is repeated correctly, a longer one is 
read continuing until the participant fails a pair of sequences, or repeats the highest 
sequence consisting of nine digits correctly. Two trials are given for each sequence length 
and one raw score is given for every correct trial. In digits backward the procedure is the 
exact same except the digit are repeated in the reverse order (Lezak, 2004; Strauss et al., 
2006). 
 
Block Design of the WAIS. The examinee is presented with red and white blocks and is 
asked to replicate models or pictures of two-color designs. During the first six trials, the 
blocks are four with a time limit of one minute but over the last four trials the blocks are 
nine and a two-minute time limit. The testing is discontinued after three consecutive 
failures (Kuzis, Sabe, Tiberti, Dorrego, and Starkstein, 1999; Strauss et al., 2006). 
 
Similarities of the WAIS. The subject is asked to describe in what way two concepts or 
objects are alike. The 13 word pairs vary in difficulty from the first “orange-banana” to 
the last “tree-alcohol”. Answers were scored according to the scoring criteria in the 
manual with two points given for an abstract generalization but one point if the answer is 
a specific concrete similarity (Kuzis et al., 1999; Lezak, 2004). 
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The Trail Making Test is administrated in two parts: A and B. The subject’s task is to 
draw a line connecting circles as fast as he can without lifting the pencil from the paper. 
In part A, the circles contain numbers from 1-25, which the subject connects in the right 
sequence. Part B has the same number of circles with half of them containing numbers (1 
to 13) and the other half letters (A to L). The subject is required to shift between numbers 
and letters while connecting the circles beginning at number “1” to letter “A” and then 
from letter “A” to number “2”, etc. The total score for each part was the time required to 
complete each trial. If three errors were made in Part A and four errors in part B without 
them being corrected, the performance was labeled as “could not finish”, and the 
individual therefore excluded from the analyses of this test. 
 
Verbal Fluency Tests 
In the Oral Word Fluency the subject is asked to name as many words as he can 
beginning with the letter “s”. Total score was obtained from number of correct words 
produced within one minute (Lezak, 2004). 
 
In the Category Fluency the subject is asked to name as many animals as he can think of. 
Total score was obtained from number of correct words produced within one minute 
(Lezak, 2004). 
 
In the Boston Naming Test the task is to name 30 line drawings of increasing difficulty, 
ranging in familiarity from common ones such as “bed” and “pencil” to rare ones such as 
“abacus”. A semantic cue is given when participants fail to name a drawing, and if still 
unable to give a correct answer a phonemic cue is presented. The number of correctly 
named drawings is the outcome measure, with drawings named after semantic and 
phonemic cues counted separately (Lezak, 2004; Strauss et al., 2006). 
 
The Gestalt Closure Test (Kaufmans ABC) consists of 25 pictures that are incomplete and 
the participant’s task is to decipher them. One point is given for every correctly identified 
picture (Lezak, 2004). 
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Recognition tests 
The same recognition tests designed for the original study were used to add short forms of 
recognition to the memory tests (Pálsson, 2002). 
 
In the Recognition of the Rey Complex figure the subject’s task is to correctly identify the 
original Rey Complex figure, copied 45 minutes earlier, among five other slightly 
changed figures presented on a single sheet. One point is given for identifying the correct 
figure, but if a wrong figure is chosen the corresponding number of that figure is recorded 
(see Appendix I, Pálsson & Jónsdóttir, unpublished). 
 
The Recognition of the Logical Memory test consist of ten multiple-form questions from 
the two stories read 45 minutes earlier. Maximum score for each story is five points and 
the final score is gathered by dividing the total scores of story A and B by two (see 
Appendix II, Pálson and Jónsdóttir, unpublished). 
 
The neuropsychological tests used in this study are grouped in six functional domains, 
where each test can measure more than one functional trait (see table 6). 
 
Table 6. 
Functional domains and neuropsychological assessment (derived from Pálsson, 2002). 
 
Neuropsychological tests and functional domains 
Orientation Language 
Orientation to person, place and time Oral Word Fluency 
Verbal and nonverbal memory Boston Naming Test 
Logical Memory (LM) delayed and immediate recall Attention and mental speed 
Recognition of LM Trails A and B 
Rey Complex Figure-delayed and immediate recall  Digit Span 
Associate Learning, Easy pairs and hard pairs Visuo-spatial and constructional abilities 
Recognition of Rey Complex Figure Block Design 
Abstract reasoning and executive function Gestalt Closure (Kaufmann-ABC) 
Similarities Rey Complex Figure, copy 
Oral Word Fluency  
Trails B  
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7.3. Procedure 
The AC and NC groups were assessed with the same neuropsychological tests on two 
occasions over a 9-year period. The first assessment took place between 1998-2000 and 
then again in 2007. On both occasions potential participants were contacted by phone. If 
they agreed to participate a letter was sent containing detailed information regarding the 
research as well as an informed written consent, which they were asked to sign. 
Neuropsychological assessment was carried out at the Genetic Research Center, deCode 
genetics and lasted approximately 1 hour, with suitable rest periods if needed. In the 
original assessment, participants were informed that no information would be provided 
regarding individuals because all results would be based on group analysis. In the 
reassessment however, participants were asked prior to testing whether they wanted their 
outcome to be compared to that of 7-9 years earlier. A clinical neuropsychologist 
assessed the performances for those that chose to be informed. If any participant showed 
indications of decline, a more comprehensive assessment was provided at a memory 
clinic at the Landspítali University Hospital. A letter informed those who showed no 
signs of cognitive decline. Both studies received ethical approval from the Data 
Protection Commission of Iceland and the Bioethics Committee of the Icelandic Health 
Ministry. 
 
 
7.4. Statistical analysis 
The performance of the AC group was compared to the performance of the NC group 
with an independent-samples t-test and a Chi-square (X2) where it applies separately for 
both assessments. Paired-samples t-test was used to look at each group’s performance 
over time. ANOVA repeated measure (2 (groups) x 2 (time 1 and time 2)) was used for 
each neuropsychological test to assess the main effects of group and time and a possible 
interaction between group and time. Because of multiple comparisons and the risk of 
Type I error the Bonferroni correction9 was used and the p-value in each t-test was 
                                                
9 The Bonferroni correction for multiple comparisons is as follows: !1 = !/c (&1 = corrected alpha level; & 
= alpha level (.05); c = number of functional domains; Howell, 1997). Instead of changing the level of 
significance in each comparison the p-value in the t-tests was corrected according to following formula (! = 
!1 * c). The number of functional domains was defined in the study as six, and they were equal to the 
number of factors according to factor analysis. 
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corrected. All the tests were two-tailed and a p<0.05 was used. The effect of age, gender 
and education was assessed with independent-samples t-test. Finally discriminant 
functional analysis (DA) was carried out in order to determine whether any of the 
individuals in these two groups scored as the AD patients (AD) or the Sibling group (Sib) 
in the original study on the neuropsychological tests. Statistical analyses were performed 
by using computerized statistical software (SPSS 11.0 for Windows software). 
 
 
8. Results 
The NC group (n=30) consisted of two groups. The first group, constituting the majority, 
were spouses of individuals in the AC group (70%), while members of the second group 
were recruited after placing an advertisement in a social center for the elderly. Given that 
no difference was apparent between the two groups on any of the neuropsychological 
measures used in the study, they were treated as a homogenous control group. 
There were no differences evident between the AC and the NC group in regard to 
the clinical variables obtained by the health questionnaire such as head trauma, blood 
pressure and metabolic diseases. The AC groups mean on the memory questionnaire was 
19 compared to 22 for the NC group, the difference being non-significant. 
Due to the exclusion criteria, 6 individuals were excluded from the statistical 
analysis. From the AC group 2 were excluded due to central and peripheral nervous 
system disorders and 4 from the control group due to severe psychiatric illness, head 
trauma, central and peripheral nervous system disorders. Recomputing the data with these 
6 individuals included showed no alteration in the results.This left the final number of 
participants at 113. As is shown in table 5, no statistical difference was found between the 
AC and the NC groups in this study in respect to age, sex, and education. 
 
8.1. Neuropsychological measures 
In table 7, mean scores are provided for the AC and the NC group on the 
neuropsychological measures at baseline assessment (time 1) in the year 1998-2000 and 
for the reassessment (time 2) in 2007. In addition the highest possible scores on each test 
are also provided. For all the neuropsychological tests used in the study, a lower score 
indicates a weaker performance accept for the Trail Making tests; where a higher score 
indicates a weaker performance, signifying a longer time spent on completing the task. 
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On the majority of the tests both groups show decline in performance between 
time 1 and time 2, with few exceptions. The AC group scored higher than baseline in the 
reassessment on immediate and delayed recall on the Rey Complex Figure, the block 
design and Similarities whereas the NC group performed better on the delayed recall of 
the Rey Complex Figure in the reassessment than at the baseline assessment. 
 
 
8.2. Comparison of AC and NC group and the effect of time 
The AC and the NC group were compared using independent-samples t-test on time 1 and 
time 2 separately. No statistical difference was evident between the two groups on any of 
the neuropsychological tests on these two points in time. 
A paired-sample t-test was conducted to independently to evaluate each group’s 
performance over time. The performance declined on all neuropsychological test from 
time 1 to time 2. Statistical analysis revealed a significant difference of the performance 
for the AC group on time 1 and time 2 on the following seven neuropsychological tests; 
Digit span forward (t(81)=3.442, p< .05), Trail Making test B (t(72)=-3.744, p< .05), 
Category fluency (t(82)=2.837, p< .05), Gestalt Closure (t(82)=2.349, p< .05), LM 
immediate (t(81)=-4.652, p< .05) and delayed recall (t(81)=5.487, p< .05) and the hard 
pairs of the Associate Learning test (t(82)=4.834, p< .05). 
For the NC group a statistical difference was evident on two of the 18 
neuropsychological tests, namely the Trail Making test A (t(29)=-3.576, p< .05) and the 
LM delayed recall (t(29)=2.901, p< .05) with the performance declining from time 1 to 
time 2 (see table 7). 
Given the limited generalizabilty of the paired t-test analysis and the many factors 
that could possibly explain the significant differences found, such as time for instance, a 
one-way repeated measure ANOVA (2 (groups) x 2 (time 1 and time 2)) was carried out 
(Pallant, 2005). This was done for every neuropsychological test separately in order to 
estimate the effects of group and time and a possible interaction. Significant difference 
for time was found on the following tests: Rey copy, immediate and delayed recall, hard 
pairs of the Associate Learning test, LM immediate and delayed recall, Oral word and 
category fluency, Boston Naming, Digit forward and Gestalt Closure. Significant 
differences between the two groups were not evident on any of the tests, nor were there 
any significant interactions between time and group, indicating that the AC and the NC 
group declined similarly in performance from time1 to time 2. 
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Table 7. 
Mean (M) and standard deviation (SD) scores for the AC and NC group on neuropsychological 
measures for baseline assessment (time 1) and the reassessment (time 2). 
  AC group 
(n=83) 
NC group 
(n=30) 
Neuropsychological tests Max. time 1 time 2 time 1 time 2 
  M* SD M* SD M* SD M* SD 
Orientation (total score) 10.00 9.96 0.19 9.93 0.26 9.97 0.18 9.97 0.18 
LM        
Immediate recall 23.50 13.89 2.98 12.77 2.50 14.37 2.63 12.92 2.45 
Delayed recall 23.50 12.26 2.89 10.87 2.77 12.20 2.31 10.94 2.32 
Association Learning 
test: 
     
Easy pairs 9.00 8.53 0.66 8.50 0.75 8.35 0.81 8.31 1.10 
Hard pairs 12.00 6.96 2.79 5.59 2.80 6.97 2.88 5.48 3.39 
Rey complex figure:        
Copy 36.00 34.46 2.07 34.03 10.80 34.57 1.79 34.00 1.89 
Immediate recall  36.00 21.08 5.66 22.43 5.39 19.87 6.49 19.83 6.95 
Delayed recall 36.00 20.93 5.30 21.64 5.73 19.62 6.08 21.08 6.60 
Verbal Fluency tests:        
Oral word fluency  * 15.42 5.41 14.75 4.95 15.57 4.86 13.27 5.30 
Category fluency * 23.31 6.28 21.61 5.45 22.17 5.22 20.43 4.42 
Boston Naming test 30.00 29.18 1.14 28.95 1.29 29.13 1.78 28.67 2.55 
Trails A, time in seconds * 33.51 11.19 36.20 11.27 34.00 9.71 41.00 13.15 
Trails B, time in seconds * 73.58 23.20 87.17 36.37 85.60 23.63 89.55 37.21 
Digit Span:        
Forward 9.00 6.52 1.39 6.04 1.21 6.43 1.10 5.93 1.23 
Backward 7.00 4.60 1.30 4.34 1.12 4.60 1.22 4.40 1.25 
Block design 19.00 13.54 2.66 13.75 2.79 14.03 1.92 13.47 2.58 
Gestalt Closure 25.00 20.22 2.92 19.63 3.17 20.38 3.20 20.03 3.53 
Similarities 19.00 14.41 2.46 14.46 2.17 15.10 1.97 14.55 2.26 
 
*Means are highlighted in table to discriminate them from the standard deviations. 
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8.3. Effects of age, gender and education on the AC and NC group in the 
reassessment 
 
 
Age 
The AC and the NC groups were divided into three groups with 10-year intervals, i.e. 46-
55, 56-65, and 66-75 years of age. The two groups were then compared on the 
neuropsychological measures within each age group. In the youngest group, 46-55, and 
the 56-65 years old age groups, no significant difference between the AC and the NC 
group was evident. In the oldest group, 66-75, a significant difference was detected 
between the two groups on the digit span forward (t(21)=-3.215, p< .05) with the AC 
group performing less well. 
 
 
Gender 
Comparison between genders in the AC and the NC groups showed no significant 
difference on any of the neuropsychological measures. 
 
 
Education 
The education level of participants in the AC and NC groups were similar, with around 
70% of the individuals having further education (more than 8 years) in both groups. The 
participants in each group were divided in two groups based on their educational status; 
those with 8 years of education or less (<8 years) and those with more than 8 years of 
education (>8 years). These two educational groups were then compared within each 
study group. 
 In the AC group a significant difference was found, with the >8 years educational 
group scoring significantly higher on Block design (t(81)=-3.001, p< .01). A significant 
difference was likewise evident in the NC group on the delayed recall of the Rey 
Complex Figure (t(28)=-2.884, p< .01), and the hard pairs of the Associate Learning test 
(t(27)=-2.871, p< .01), with those with further education >8 years scoring higher. This 
latter difference could possibly be due to the fact that of the 30 individuals in the NC 
group only 8 had elementary education (<8 years). 
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8.4. Comparison of the AD, Sib, AC and NC groups from time 1 assessment 
Comparison of the AC and the NC groups on the neuropsychological tests indicate little 
difference between the two groups 
Next step of the analysis was to compare the performance of the AC and the NC 
groups from time 1 to the performance of the AD patients that had recently been 
diagnosed (N=76) and the Sibling group (Sib) (N=92) tested in the original study between 
the years 1998-2000. The purpose was to find out using discriminant functional analysis 
if any from the AC and the NC groups from scored similarly as the AD and the Sib group 
on any of the neuropsychological measures. On demographical variables the four groups 
differed with respect to age and education with the AD and Sib groups being statistically 
older than the AC and NC groups and less educated (see table 8). 
 
Table 8. 
Demographics for the AD, Sib, AC and NC group, time 1 assessment. 
 AD 
N=76 
Sib 
N=92 
AC 
N=83 
NC 
N=30 
Age (years)     
Average 75.0 72.4 52.2 53.8 
Standard deviation 5.5 7.0 7.0 7.1 
Range 61-85 55-85 40-68 43-66 
Sex     
Women 34 (45%) 50 (54%) 49 (59%) 14 (47%) 
Men 42 (55%) 42 (46%) 34 (41%) 16 (53%) 
Education     
%  8 44 (58%) 51 (55%) 26 (31%) 8 (27%) 
%  8 32 (42%) 41 (45%) 57 (69%) 22 (73%) 
 
Post hoc comparison revealed, as expected, that the AD and the Sib groups showed 
impaired performance compared to the AC and the NC groups on all the 
neuropsychological tests apart from the Orientation total score and the Similarities of the 
WAIS where the difference between the Sib, AC and NC groups were non-significant. 
Caution must be advised in interpreting these results given the difference in age and 
education between the groups. 
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8.5. Grouping of participants according to scores on the neuropsychological 
measures for time 1 and time 2 assessments. 
In the original study from 2000, seven of the 18 neuropsychological tests seem to have 
higher predictive value in dividing the Sib group into two separate groups. They were 
labeled “impaired Sibs”, scoring similar to the AD patients, and “intact Sibs”, scoring 
more like the NC group. These test were: orientation total score, immediate and delayed 
recall for the LM and the Rey complex figure, Trail Making test A and the hard pairs of 
the Associate learning test (Pálsson, 2002). 
Discriminant function analysis was carried out to see if any of the individuals in 
the AC or the NC groups at the baseline assessment scored similar to the Sib group or AD 
group on the seven tests mentioned above. A significant difference between the group 
centroids was evident from the canonical correlation analysis indicating that the group 
means differ for function 1 and 2 (Wilk’s Lambda of .221, p<0.001) but not for function 3 
(see figure 1). 
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Figure 1. 
Canonical analysis of how participants in the AD, Sib, AC and the NC groups fall within 
two-dimensional scales on test of verbal and nonverbal immediate and delayed recall, 
orientation, mental speed and attention. 
 
Delayed recall of the LM had the highest correlation with the canonical discriminant 
functions. Next came the delayed recall of the Rey figure and then the immediate recall of 
the LM (see table 9). 
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Table 9. 
Highest correlation between the variable and the canonical discriminant function ordered 
by the magnitude of the correlation. 
 Function 1 Function 2 Function 3 
Delayed recall of LM .840 .048 .123 
Delayed recall of Rey figure .736 .346 .386 
Immediate recall of LM .725 .007 .576. 
Immediate recall of Rey figure .646 .354 .324 
Hard pairs of the Associate Learning .571 .293 324 
Trail Making test A .583 .714 .003 
Orientation total score .390 .011 .019 
 
According to the discriminant functional analysis, no individuals in the AC or NC group 
scored in a manner resembling the AD group on the neuropsychological test. However, 
16% of the AC group and 7% of the NC group were classified as scoring more like the 
Sib group rather than their own group. This group of AC (n=13) had a significantly 
higher mean age (63 years; s= 6.7; range= 52-74) compared to rest of the AC (n=70), 
with a mean age of 58 years (s=6.7; range 46-74; t(81)=2.381, p< .05). No difference was 
found between the two groups with respect to education. No one in the AD group was 
classified with the NC group and only 3% with the AC group. In the Sib group 11 % had 
more resemblance to the AC group than their own group. The analysis revealed 64.1% of 
the original cases to be correctly classified (see table 10). 
 
Table 10.  
Predicted group membership of the AD, Sibs, AC and NC groups from time 1 according 
to discriminant analysis. 
Predicted group membership 
Participants AD 
N   (%) 
Sib 
N   (%) 
AC 
N   (%) 
NC 
N   (%) 
AD 62 (81.6) 12 (15.8) 2 (2.6) 0  
Sib 12 (13.0) 61 (66.3) 10 (10.9) 9 (9.8) 
AC 0 13 (15.7) 42 (50.6) 28 (33.7) 
NC 0  2 (6.7) 13 (43.3) 15 (50.0)  
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Discriminant functional analysis was also conducted for the reassessment of the AC and 
the NC groups, in which they were compared to the same AD group and Sib group as in 
the previous analysis. The purpose was to detect the following. Firstly, if those 
individuals previously classified as scoring similarly to the Sib group still did so in the 
second study. Secondly, do any off these individuals now resemble the AD patients in 
their scoring on the neuropsychological tests. Thirdly, is there an addition to those 
individuals in the AC or the NC group classified as either Sibs or AD patients. 
As in the former canonical correlation analysis, a significant difference was 
evident between the group centroids, indicating that the group means differ for function 1 
and 2 and also for function 3 (Wilk’s Lambda of .221, p<0.001; see figure 2). 
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Figure 2.  
Canonical analysis of how participants in the AD and Sib from time 1, and the AC and 
NC group from time 2 fall within a two-dimensional scales on test of verbal and 
nonverbal immediate and delayed recall, orientation, mental speed and attention. 
 
As in the previous analysis, the canonical variables are three in number, with the highest 
eigenvalue (2.138) corresponding to the maximum spread of the group means or as high 
as 86.5% of the variance, the second eigenvalue (0.283) for 11.4% and the third (0,051), 
now being significant, accounted for only 2.1% of the variance. 
In the latter analysis the delayed recall of the Rey figure had the highest 
correlation with the canonical discriminant functions, with the delayed recall of the LM 
coming second and then the immediate recall of the Rey figure (see table 11). 
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Table 11. 
Highest correlation between the variable and the canonical discriminant function ordered 
by the magnitude of the correlation for the second analysis. 
 Function 1 Function 2 Function 3 
Delayed recall of Rey figure  .819 .505 .096 
Delayed recall of LM .802 .064 .049 
Immediate recall of Rey figure  .747 .553 .294 
Immediate recall of LM .721 .095 .001 
Orientation total score .640 .594 .259 
Hard pairs of the Associate Learning .458 .080 .038 
Trail Making test A .397 .006 .172 
 
Discriminant functional analysis of the reassessment revealed that one individual (1.2%) 
in the AC group had a score resembling the AD patients, as opposed to no one in the NC 
group. This individual was 60 years of age and with an education under 8 years. Around 
17% of the AC group and 13% of the NC group were classified as scoring similarly to the 
Sib group. This group of AC (n=14), scoring in resemblance to the sib group, had an 
significantly higher mean age (64 years; s= 6.7; range= 52-74) compared to rest of the 
AC (n=69), with a mean age of 58 years (s=6.4; range 46-72; t(81)=3.382, p< .05). 
Furthermore the two groups differed in education with the AC group scoring as the sib 
group having lower education, X2 (1, N=83)=3.874, p<.05. As in the previous analysis, no 
AD patients were grouped with the NC group but 3 (3.9%) were classified as scoring like 
the AC group. Lastly 15% of Sib group resembled the AC group in their scoring. The 
analyses revealed that 66.5% of the original cases were correctly classified (table 12). 
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Table 12.  
Predicted group membership of the AD, Sibs from time 1, and AC and NC groups from 
time 2 according to discriminant analysis. 
Predicted group membership 
Participants AD 
N   (%) 
Sib 
N   (%) 
AC 
N   (%) 
NC 
N   (%) 
AD 61 (80.3) 12 (15.8) 3 (3.9) 0  
Sib 10 (10.9) 58 (63.0) 14 (15.2) 10(10.9) 
AC  1 (1.2) 14 (16.9) 51 (61.4) 17 (20.5) 
NC 0  4 (13.3) 9 (30.0) 17 (56.7)  
 
Comparing the two discriminant functional analysis revealed that one of the 13 
individuals classified as scoring like the Sibs in the first analysis now resembled the AD 
patients the most. Eight individuals were still grouped as belonging in the Sib group 
(ACstill), three individuals were now grouped in their own group (AC) and one in the NC 
group. Finally six new individuals in the AC group (ACnew) seemed to score like the Sib 
group, having scored like the rest of the AC in the former analysis (see table 13). 
 
Table 13. 
Comparison of the AC group classification in discriminant analysis from the years 2000 
and 2007 with respect to age and education. 
 ACstill 
n=8 
ACnew 
n= 6 
Other AC 
n=69 
Age (years)    
Average 62.5 67.0 58.0 
Standard deviation 7.6 4.8 6.4 
Range 52-74 60-74 46-72 
Education    
%  8 6 (75%) 2 (33%) 18 (26%) 
>  8 2 (25%) 4 (67%) 51 (74%) 
 
As can been seen from table 13, interestingly those individuals belonging to the ACstill 
group were relatively younger than those in the ACnew group. When compared to the 
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other AC group the ACnew group was statistically older (t(73)=3.344, p< .05), but the 
ACstill group not. With respect to education the ACstill group on the other hand was 
statistically less educated, X2 (1, N=77)=5.877, p<.05 than the other AC group, but the 
ACnew group not. 
 
 
9. Discussion 
In the current study, a group of individuals with at least one parent diagnosed with AD 
were compared to a group of individuals without any first-degree relatives with dementia 
at two points in time, with a 7-year interval. The aim of the study was threefold: 1) To 
examine if adult children of AD patients are more likely to show cognitive impairment 
compared to a group of individuals with no first-degree relatives suffering from dementia; 
2) To estimate whether the adult children of AD patients show faster decline on any of 
the neuropsychological measures compared to the control group; 3) To determine which 
neuropsychological tests best differentiate between the two groups. The groups were age, 
gender and education matched. Furthermore no differences were found between the two 
groups on health variables measuring factors that might affect cognitive performance, nor 
the Memory Observation Questionnaire, leaving the family history as the only 
distinguishing factor. The AC and the NC groups were compared on standardized 
neuropsychological tests that are widely used and regarded as being sensitive to the 
preclinical stages of the disease. The tests measured cognitive domains of orientation, 
memory, abstract reasoning and executive functioning, language, attention and mental 
speed, and visual-spatial abilities. Previous studies have shown first-degree relatives of 
AD patients to be at higher risk of developing the disease and that early cognitive change 
can be detected on neuropsychological test prior to the appearance of overt clinical signs. 
In recent years interest in adult children of AD patient has increased. Studies on this at 
risk group are scarce and, unfortunately, many of them are poorly designed and have 
yield mixed results. 
The primary findings of the current study were that no statistical differences were 
found between the adult children of Alzheimer’s patients and a group of individuals 
without family history of dementia on any of the neuropsychological measures. 
When all the participants were compared on their own performance during 
baseline and the reassessment, decline was evident on more than half of the 
neuropsychological measures. These were the: LM of the WMS (immediate and delayed 
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recall), Rey Complex Figure (immediate and delayed recall) measuring verbal and 
nonverbal memory; oral and category fluency on the Verbal Fluency Test and Boston 
Naming Test measuring language and executive functioning, Digit Span forward of the 
WMS measuring attention and mental speed, and the Gestalt Closure and Rey Complex 
Figure measuring visuo-spatial and constructional abilities. This is in accordance with the 
literature demonstrating the effects of aging (time) on cognitive abilities (see in Lezak, 
2004; Strauss et al., 2006). 
Even though general decline was evident over the 7-year period on some of the 
cognitive measures, no statistical difference was found in decline between the AC and the 
NC groups. This means that the AC and the NC groups seem to have declined to the same 
extent between the two assessments making the general effects of aging a likely 
explanation. Another contributing factor might be tester effect given that different 
individuals administered the neuropsychological test at the baseline assessment than in 
the reassessment. Differences in personal testing styles and scoring methods, although 
every measure were taken to prevent such a bias, might possibly account to some extent 
for the equal decline found in both groups. 
The above findings are in line with the few reports published on children of AD. 
In what most likely constitutes the first study examining the adult children of AD 
exclusively, Smalley and associates (1992) reported that performance on measures of 
verbal memory, visuo-spatial memory and selective reminding was not less than age-
matched norms. The sample included 106 adult children with a mean age of 40,6 year. In 
a 20-year follow up on 25 adult children (mean age 62 years) from the original sample, 
Jarvik, La Rue and associates (2005) reported decline on only one of eleven measures, the 
Digit symbol of the WAIS. Again, as in the original assessment from 1992, no 
comparison group was provided. In an attempt to tackle this shortcoming, Ercoli and 
colleagues (2005) compared the same 25 adult children to an age comparable sample of 
24 healthy individuals with no family history of AD. According to their findings, the 
children scored significantly lower than the control group on the MMSE of the six 
cognitive measures used in the study. The results of the current study confirm what less 
well-designed studies have indicated, namely that adult children of AD patients, with a 
mean age around 60, do not exhibit poorer cognitive performance than those without any 
family history of the disease. 
When studies of mixed samples of first-degree relatives are examined, the 
majority indicates decline or impairment in cognitive performance compared to a control 
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group (Bondi et al., 1994; Díaz et al., 1997; Fox et al., 1998; Hom et al., 1994; LaRue, et 
al., 1995), which contradicts the findings of the current study with two exceptions (Small 
et al., 1994; 1995). Furthermore, studies researching siblings exclusively have reported 
even stronger evidence of such a difference (Pálsson and Pálmason, 2001; Pálsson and 
Teague, 2007; Rice et al., 2003). Based on this, one might conclude that adult children 
and siblings of AD patients constitute different subtypes of AD, with different 
presentation and timing of symptoms. However, when these studies are examined with 
respect to average age participants, sample size and study designs, a different and more 
likely suggestion becomes evident. In the studies conducted by Díaz et al. (1997) and Fox 
et al. (1998) the average age of participants is 36 and 45 respectively, much lower than in 
the current study. Furthermore, the main aim of the studies was the investigation of the 
autosomal dominant familial (early onset) AD, rather than late onset. The opposite is 
evident with Bondi et al. (1994), Pálsson and Pálmason (2001), Pálsson and Teague 
(2007), and Rice et al. (2003). In these studies the average age samples are up to 20 years 
older than in the current study, ranging from 70 to 79 years. This makes direct 
comparison to current findings difficult. In the studies conducted by Hom et al. (1994) 
and LaRue et al. (1995), the average mean age is similar to that in the present study, 
around 60 years. However, the sample sizes are relatively small, especially in Hom et al. 
where there are only 20 adult children and only one cross-sectional measure is conducted. 
But reports from cross-sectional studies have shown an overestimation of cognitive 
decline due to cohort effects (Collie and Maruff, 2000; Small, 2001; see also in Lezak, 
2004). In LaRue et al. (1995), longitudinal measures are provided but no information as 
to how many adult children opposed to siblings are in the sample, which makes a 
concrete conclusion difficult. In the context of the current study, as well as previous 
findings on adult children, the most likely reason why no difference was found between 
the AC and the NC group is that the sample is too young. Cognitive differences found 
between siblings and controls, most notably in samples with higher average age, are 
simply not detectable yet. 
Findings from the current study, when the performance of each group over time 
was evaluated separately, support the above suggestion. On this measure, the AC group 
showed significant decline on seven cognitive measures, compared to two in the NC 
group. These were measures on Digit Span Forward of the WAIS; Trail Making Test B, 
Category fluency of the Verbal Fluency Test; Gestalt Closure; immediate and delayed 
recall on the LM of the WAIS; and the hard pairs of the Associate Learning test. 
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Interestingly, the domains that these test measure are memory, executive functioning and 
mental speed and attention, which by many are regarded as the most sensitive to cognitive 
deficits in preAD (Bäckman et al., 2005; Twamley et al., 2006). However, when the 
effects of time, group and possible interactions there between were taken into account, 
these effects disappeared. In light of the low average age of the AC group, those children 
that will eventually develop AD are probably in the earliest stages of the preclinical 
phase. Studies have shown the earliest stages of the preclinical phase to be characterized 
mostly by early pathological changes but also very mild or no cognitive impairments 
(Dubois, 2000). When these individuals become older, reaching the age of 70 and above, 
their compensatory mechanisms (cognitive reserve), which have up to this point made 
them parallel to the control group, start to diminish. This might result in their previously 
undetectable cognitive deficits becoming overt, as is apparent in the sibling studies 
discussed above. Such a pattern would be in line with findings from studies on preAD 
which indicate that cognitive impairments, after onset, seem to remain stable until three to 
four years before diagnosis, which is when a precipitous decline occurs (Båckman et al., 
2005; Twamley et al., 2006). Most studies have shown changes in cognitive performance 
up to 6 years before diagnosis (Båckman et al., 2001; Small et al., 2000), although others 
have reported changes up to 15 years before diagnosis (Kawas et al., 2003; Snowdon, 
1997; Snowdon et al., 1996). There has been a clear lack of consensus as to when the 
preclincal period begins and early preclinical changes may be detected. This is partially 
due to the fact that most studies on preAD use either relatively short test-retest intervals 
(two to three years after initial assessment) or longer intervals (decades or more). 
Although likely to detect changes with longer intervals, realizing the exact onset of the 
decline is more difficult (Twamley et al., 2006). Regarding these problems, the following 
two conclusions, related to adult children of AD patients, can be drawn from the current 
study. Firstly, compared to a control group without any family history of AD, no clear 
signs of cognitive impairment are apparent in adult children of AD patients up until the 
age of 60. Secondly, that a 7-year test-retest interval is sufficient when evaluating adult 
children of AD patients under the age of 60 longitudinally with neuropsychological tests. 
Only time will reveal how many from the AC group eventually develop AD and 
whether their first impairments will resemble those of the Sib group, as found in the 
original study conducted in 2000 and again in the reassessment of that group six years 
later (Pálsson, 2002; Pálsson and Teague, 2007). However, given the vague indication of 
an accumulation of cognitive impairment in the AC group their performance was 
 73 
compared to the scores of the AD group and the Sib group from the original study. This 
was done separately both for the baseline assessment and reassessment. The purpose was 
to see if any of the individuals in the AC and NC groups at these two points in time 
scored similarly to the AD patients and the Sib group with a 20-year higher average age. 
In the Sib study from 2002, seven tests seem to have higher predictive value in dividing 
the Sib group into two separate groups, impaired sibs (scoring similar to AD group) and 
intact sibs (scoring more like the NC group (Pálsson, 2002). The AD, Sib, AC and NC 
groups were compared using discriminant analysis on the following seven 
neuropsychological tests: Orientation, Trails A, hard pairs of the Associate Learning test, 
and the immediate and delayed recall of the LM of the WAIS and Rey Complex Figure. 
 When comparing the baseline performance of the AC and the NC to the AD and 
Sib groups, delayed recall of LM and Rey Complex Figure had the strongest weight when 
regrouping the individuals according to the seven cognitive measures. Thereafter came 
the immediate LM and Rey Complex figure, hard pairs of the Associate Learning Test, 
Trail Making Test A and Orientation respectively. According to the discriminant analysis, 
no one from the AC or NC groups scored in a fashion similar to the AD patients on the 
neuropsychological tests. However, 16% of the AC group and 7% of the NC were 
considered to score similarly to the Sib group. Interestingly, 3% of the AD patients were 
regrouped to the AC group (see table 10). 
 Comparison of the performance of the AC and the NC during reassessment to the 
AD and the Sib groups from the original study was conducted for the following reason. 
To examine if the pattern of individuals previously regrouped from the original 
classification was the same seven years later or if any changes were apparent. Like in the 
previous discriminant analysis, delayed recall of the Rey Complex Figure and LM had the 
most weight, followed by immediate recall of the Rey Complex Figure and LM. 
Thereafter came the Orientation, hard pairs of the Associate Learning Test and the Trail 
Making Test A respectively. Unlike the previous analysis, one individual from the AC 
group scored in most resemblance to the AD patients, while 17% of the AC and 13% of 
NC were regrouped as Sibs. Now 4% of the AD patients were regrouped into the AC 
group (see table 12). When comparing the two analyses, one of the 13 individuals 
regrouped as Sibs in the first analysis now resembles the AD patients most intest scores. 
Eight individuals were still grouped as scoring most closely to the Sib group; three were 
now, seven years later, grouped back to their original AC group and one in the NC group. 
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Finally, six new individuals from the AC group were regrouped to the Sib group having 
scored like the rest of the children in the former analysis. 
 What is interesting in these findings, although great caution must be taken with 
any further interpretation, is how many children are regrouped with the Sib group, whose 
members are on average 13 years older. This is especially interesting in light of the fact 
that no difference was found between the AC group and NC group on any of the 
neuropsychological tests. Notably some from the NC were also regrouped to the Sib 
group but not to the same extent as in the AC group. Furthermore, eight individuals from 
the AC group kept their regrouping status as scoring more similar to the Sibs and one, 
now seven years later, was regrouped as AD, indicating a possible progression trend. 
However four children regrouped as Sibs in the previous analysis were now grouped back 
to the AC group and one to the NC group. That, however, is not necessarily surprising 
and might reflect the challenges of preclinincal diagnosis of AD due to the overlap of 
normal and initial signs of cognitive impairment. In addition, individual differences with 
respect to cognitive abilities and compensatory mechanisms can be relevant, as is 
probably evident with the six new children regrouped with as Sibs. Of course, further 
statistical analysis is needed to explore this specific group of children classified as much 
older Sibs but comparison is difficult given the limited number of individuals, and is 
beyond the scope of this study. However, the clinical evaluation of the individual 
regrouped as AD is worth mentioning. Evaluation strongly indicated a diagnosis of 
probable AD, giving support to the sensitivity of the seven neuropsychological tests used, 
as well as the efficiency of the discriminant analysis. 
 
 
10. Conclusion and future research 
When taking the threefold aims of the study under scrutiny, it is evident that all of them 
have been addressed and clarified at least partially. Firstly, no cognitive impairment was 
found in adult children of AD patients compared to a group of individuals without any 
family history of AD. Secondly, mild general cognitive decline was apparent between the 
two measurements, but equally within both groups indicating the general effects of aging. 
However, when the performance of the groups was compared independently between the 
baseline and reassessment, a trend in cognitive decline was evident among the children. 
This might, when placed in context with the literature, be regarded as vague indication of 
the earliest stages of preclinical AD. It is important that this trend disappeared when the 
 75 
effects of time, group and interaction were taken into the equation. Thirdly, in light of no 
difference being found between the two groups, finding which cognitive measures best 
differentiates them is meaningless. However, by using measures shown to be effective in 
identifying impaired Siblings of AD patients, indications of what might be an isolated 
group of children in progression to AD were found. Finally, in addition to this, findings 
from the study support what previous studies have indicated, namely that adult children 
of AD patients remain cognitively intact up to the age of 60. Some light has furthermore 
been shed on what constitutes an appropriate length of test-retest interval in research on 
this group. 
When interpreting the above it is important to keep in mind the relatively young 
average age of the sample, which most likely explains why no cognitive decline was 
apparent. As discussed above only time and future reassessment can tell whether any of 
these individuals eventually develop AD and if those trends and implication drawn from 
the data are valid or not. However, the fact remains that the current study has provided 
important and much needed results on children of AD patients. Previous studies have 
been poorly designed and with small sample sizes making evaluations of this at risk 
group difficult. This study on the other hand has what seems to be the largest samples size 
yet employed in a longitudinal study conducted on children of AD patients. It has 
presented two reliable measures of the cognitive status of what seem to be asymptomatic 
children of AD patients. Future reassessment, along with comparison to the siblings from 
the original study, could provide important information regarding the beginning and 
development of the preclinical stages in late onset AD. Furthermore, in the original study 
blood samples were taken from almost every individual taking part and their genotype 
studied, which makes APOE comparison in the future possible. Longitudinal results are 
awaited from two large cohort studies, the ACS and WRAP on children of AD patient 
(Coats and Morris, 2005; Sager et al., 2005). Although they will both represent a large 
sample size, their individual shortcomings reflect a general problem in research on early 
diagnosis of AD. The ACS study includes comprehensive clinical and psychometric 
assessment, genetic analysis and long awaited PET imaging. However the cognitive 
measures include are only one, the MMSE. The WRAP on the other hand has a large and 
impressive neuropsychological battery and other aspects similar to the ACS study but 
lacks neuroimaging measures. Today it is clear that the only way to make significant 
advances in research on preAD and AD in general is by combining neuropsychological, 
genetic and neuroimaging research. 
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Appendix 
 
Appendix I 
Rey Osterrieth Complex Figure Recognition Test 
In the recognition of the Rey Osterrieth Complex Figure Test the subject has to judge 
which one of following six pictures (see appendix I) is the original Rey Osterrieth 
Complex Figure that he copied 45 minutes earlier. If he fails to recognize the right picture 
the number of the wrong picture is written down, because the picture selected can be 
useful in identifying the deficits (Palsson & Jonsdottir, unpublished). 
 
Appendix II 
Logical Memory Recognition 
The recognition of the Logical Memory consists of ten questions regarding the stories 
read 45 min earlier. The examiner states the questions in a multiple choice form, and the 
subject has to choose the right answer from three possibilities (see appendix II). For each 
story the subject can score a maximum of five points. The total score for story A and 
story B is divided by two to obtain the final score (Palsson & Jonsdottir, unpublished). 
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APPENDIX II 
 
Logical Memory (WAIS) Recognition 
Correct answer is underlined . each correct answer gives one point 
Story a)    
 
Answer  
 
 1) Was the name of the woman attacked:  
 Violet Anna Susan _______ 
 2) Was she employed as:  
 Waitress Baby sitter House cleaner _______ 
 3) She was attacked and robbed of:  
 $ 15 $ 1,015 $ 50 _______ 
 4) Did she have:  
 2 children 4 children 6 children _______ 
 5) They had not eaten for:  
 7 days 4 days 2 days _______ 
 Correct answers in story a) _______ 
   
Story b)     
 1) The liner that perished was:  
 British Norwegian American _______ 
 2) Did it struck a:  
 Iceberg Mine Submarine _______ 
 3) The accident occurred last:  
 Monday evening Tuesday noon Saturday evening _______ 
 4) The number of passengers saved were:  
 18 60 350 _______ 
 5) The British ship that saved the passengers and brought into port was: 
 Fishing ship Liner Steamer _______ 
 Correct answers in story b) _______ 
 
 
Total correct answers in both stories (a + b)/2  _______  
 
